You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameMorphine
Accession NumberDB00295  (APRD00215)
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionThe principal alkaloid in opium and the prototype opiate analgesic and narcotic. Morphine has widespread effects in the central nervous system and on smooth muscle. [PubChem]
Structure
Thumb
Synonyms
(-)-Morphine
(−)-morphine
(5alpha,6alpha)-17-Methyl-7,8-didehydro-4,5-epoxymorphinan-3,6-diol
(5alpha,6alpha)-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
(5R,6S,9R,13S,14R)-4,5-Epoxy-N-methyl-7-morphinen-3,6-diol
(7R,7AS,12bs)-3-methyl-2,3,4,4a,7,7a-hexahydro-1H-4,12-methano[1]benzofuro[3,2-e]isoquinoline-7,9-diol
Morfina
Morphia
Morphin
Morphine
Morphinum
Morphium
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Avinzacapsule, extended release90 mg/1oralSTAT Rx USA LLC2002-03-20Not applicableUs
Avinzacapsule, extended release60 mg/1oralbryant ranch prepack2002-03-20Not applicableUs
Avinzacapsule, extended release120 mg/1oralbryant ranch prepack2002-03-20Not applicableUs
Avinzacapsule, extended release60 mg/1oralPfizer Laboratories Div Pfizer Inc2002-03-20Not applicableUs
Avinzacapsule, extended release45 mg/1oralPfizer Laboratories Div Pfizer Inc2002-03-202015-11-30Us
Avinzacapsule, extended release120 mg/1oralLake Erie Medical DBA Quality Care Products LLC2011-10-25Not applicableUs
Avinzacapsule, coated, extended release60 mg/1oralLake Erie Medical DBA Quality Care Products LLC2011-10-25Not applicableUs
Avinzacapsule, extended release30 mg/1oralbryant ranch prepack2002-03-20Not applicableUs
Avinzacapsule, extended release75 mg/1oralPfizer Laboratories Div Pfizer Inc2002-03-202015-11-30Us
Avinzacapsule, extended release60 mg/1oralSTAT Rx USA LLC2002-03-20Not applicableUs
Avinzacapsule, extended release90 mg/1oralPfizer Laboratories Div Pfizer Inc2002-03-20Not applicableUs
Avinzacapsule, extended release90 mg/1oralLake Erie Medical DBA Quality Care Products LLC2011-10-25Not applicableUs
Avinzacapsule, extended release90 mg/1oralbryant ranch prepack2002-03-20Not applicableUs
Avinzacapsule, extended release120 mg/1oralPfizer Laboratories Div Pfizer Inc2002-03-20Not applicableUs
Avinzacapsule, extended release30 mg/1oralPfizer Laboratories Div Pfizer Inc2002-03-202015-12-29Us
Avinzacapsule, extended release30 mg/1oralSTAT Rx USA LLC2002-03-20Not applicableUs
Bar-morphine SRtablet (extended-release)60 mgoralBard Pharmaceuticals (1990) IncNot applicableNot applicableCanada
Bar-morphine SRtablet (extended-release)100 mgoralBard Pharmaceuticals (1990) IncNot applicableNot applicableCanada
Bar-morphine SRtablet (extended-release)15 mgoralBard Pharmaceuticals (1990) IncNot applicableNot applicableCanada
Bar-morphine SRtablet (extended-release)200 mgoralBard Pharmaceuticals (1990) IncNot applicableNot applicableCanada
Bar-morphine SRtablet (extended-release)30 mgoralBard Pharmaceuticals (1990) IncNot applicableNot applicableCanada
Doloral 1syrup1 mgoralLaboratoire Atlas Inc1985-12-31Not applicableCanada
Doloral 5 Sirop 5mg/mlsyrup5 mgoralLaboratoire Atlas Inc1991-12-31Not applicableCanada
Duramorphinjection1 mg/mLepidural; intrathecal; intravenousWest Ward Pharmaceutical Corp.1984-09-18Not applicableUs
Duramorphinjection.5 mg/mLepidural; intrathecal; intravenousWest Ward Pharmaceutical Corp.1984-09-18Not applicableUs
Infumorph 200injection, solution10 mg/mLepidural; intrathecalWest Ward Pharmaceutical Corp.1984-09-18Not applicableUs
Infumorph 500injection, solution25 mg/mLepidural; intrathecalWest Ward Pharmaceutical Corp.1984-09-18Not applicableUs
Kadiancapsule, extended release30 mg/1oralbryant ranch prepack2009-04-07Not applicableUs
Kadiancapsule, extended release100 mg/1oralLake Erie Medical DBA Quality Care Products LLC2012-02-29Not applicableUs
Kadiancapsule, extended release130 mg/1oralActavis Kadian LLC2012-05-07Not applicableUs
Kadiancapsule, extended release40 mg/1oralActavis Pharma, Inc.2012-05-07Not applicableUs
Kadiancapsule, extended release30 mg/1oralLake Erie Medical DBA Quality Care Products LLC2009-04-07Not applicableUs
Kadiancapsule, extended release20 mg/1oralLake Erie Medical DBA Quality Care Products LLC2011-12-21Not applicableUs
Kadiancapsule, extended release30 mg/1oralActavis Kadian LLC2009-04-07Not applicableUs
Kadiancapsule, extended release50 mg/1oralPhysicians Total Care, Inc.2001-11-07Not applicableUs
Kadiancapsule, extended release20 mg/1oralSTAT Rx USA LLC2009-04-07Not applicableUs
Kadiancapsule, extended release80 mg/1oralActavis Kadian LLC2009-04-07Not applicableUs
Kadiancapsule, extended release20 mg/1oralActavis Pharma, Inc.2009-04-07Not applicableUs
Kadiancapsule, extended release200 mg/1oralSTAT Rx USA LLC2009-04-07Not applicableUs
Kadiancapsule, extended release20 mg/1oralActavis Kadian LLC2009-04-07Not applicableUs
Kadiancapsule, extended release60 mg/1oralbryant ranch prepack2009-04-07Not applicableUs
Kadiancapsule, extended release60 mg/1oralSTAT Rx USA LLC2009-04-07Not applicableUs
Kadiancapsule, extended release80 mg/1oralLake Erie Medical DBA Quality Care Products LLC2012-02-29Not applicableUs
Kadiancapsule, extended release150 mg/1oralActavis Kadian LLC2012-05-07Not applicableUs
Kadiancapsule, extended release50 mg/1oralActavis Pharma, Inc.2009-04-07Not applicableUs
Kadiancapsule, extended release60 mg/1oralPhysicians Total Care, Inc.2008-01-16Not applicableUs
Kadiancapsule, extended release30 mg/1oralLake Erie Medical DBA Quality Care Products LLC2011-12-21Not applicableUs
Kadiancapsule, extended release60 mg/1oralActavis Kadian LLC2009-04-07Not applicableUs
Kadiancapsule, extended release100 mg/1oralPhysicians Total Care, Inc.2008-11-20Not applicableUs
Kadiancapsule, extended release100 mg/1oralSTAT Rx USA LLC2009-04-07Not applicableUs
Kadiancapsule, extended release200 mg/1oralActavis Pharma, Inc.2009-04-07Not applicableUs
Kadiancapsule, extended release50 mg/1oralActavis Kadian LLC2009-04-07Not applicableUs
Kadiancapsule, extended release50 mg/1oralSTAT Rx USA LLC2009-04-07Not applicableUs
Kadiancapsule, extended release200 mg/1oralActavis Kadian LLC2009-04-07Not applicableUs
Kadiancapsule, extended release60 mg/1oralActavis Pharma, Inc.2009-04-07Not applicableUs
Kadiancapsule, extended release10 mg/1oralPhysicians Total Care, Inc.2008-11-19Not applicableUs
Kadiancapsule, extended release50 mg/1oralLake Erie Medical DBA Quality Care Products LLC2012-02-29Not applicableUs
Kadiancapsule, extended release40 mg/1oralActavis Kadian LLC2012-05-07Not applicableUs
Kadiancapsule, extended release10 mg/1oralActavis Pharma, Inc.2009-04-07Not applicableUs
Kadiancapsule, extended release20 mg/1oralbryant ranch prepack2009-04-07Not applicableUs
Kadiancapsule, extended release80 mg/1oralSTAT Rx USA LLC2009-04-07Not applicableUs
Kadiancapsule, extended release80 mg/1oralActavis Pharma, Inc.2009-04-07Not applicableUs
Kadiancapsule, extended release10 mg/1oralLake Erie Medical DBA Quality Care Products LLC2012-02-29Not applicableUs
Kadiancapsule, extended release100 mg/1oralActavis Kadian LLC2009-04-07Not applicableUs
Kadiancapsule, extended release20 mg/1oralPhysicians Total Care, Inc.2001-11-07Not applicableUs
Kadiancapsule, extended release30 mg/1oralSTAT Rx USA LLC2009-04-07Not applicableUs
Kadiancapsule, extended release10 mg/1oralActavis Kadian LLC2009-04-07Not applicableUs
Kadiancapsule, extended release100 mg/1oralActavis Pharma, Inc.2009-04-07Not applicableUs
Kadiancapsule, extended release30 mg/1oralPhysicians Total Care, Inc.2004-01-16Not applicableUs
Kadiancapsule, extended release60 mg/1oralLake Erie Medical DBA Quality Care Products LLC2012-02-29Not applicableUs
Kadiancapsule, extended release70 mg/1oralActavis Kadian LLC2012-05-07Not applicableUs
Kadiancapsule, extended release30 mg/1oralActavis Pharma, Inc.2009-04-07Not applicableUs
Kadian Capsulescapsule (sustained-release)50 mgoralBgp Pharma Ulc1996-10-23Not applicableCanada
Kadian Capsulescapsule (sustained-release)10 mgoralBgp Pharma Ulc2001-12-11Not applicableCanada
Kadian Capsulescapsule (sustained-release)100 mgoralBgp Pharma Ulc1996-10-25Not applicableCanada
Kadian Capsulescapsule (sustained-release)20 mgoralBgp Pharma Ulc1996-10-25Not applicableCanada
Kadian ERcapsule20 mg/1oralSt Marys Medical Park Pharmacy2010-12-21Not applicableUs
M-esloncapsule (extended release)60 mgoralEthypharm Inc1993-12-31Not applicableCanada
M-esloncapsule (extended release)10 mgoralEthypharm Inc1993-12-31Not applicableCanada
M-esloncapsule (extended release)200 mgoralEthypharm Inc1995-12-31Not applicableCanada
M-esloncapsule (extended release)30 mgoralEthypharm Inc1993-12-31Not applicableCanada
M-esloncapsule (extended release)15 mgoralEthypharm Inc1995-12-31Not applicableCanada
M-esloncapsule (extended release)100 mgoralEthypharm Inc1993-12-31Not applicableCanada
M-eslon Ircapsule (immediate release)20 mgoralEthypharm IncNot applicableNot applicableCanada
M-eslon Ircapsule (immediate release)30 mgoralEthypharm IncNot applicableNot applicableCanada
M-eslon Ircapsule (immediate release)5 mgoralEthypharm IncNot applicableNot applicableCanada
M-eslon Ircapsule (immediate release)10 mgoralEthypharm IncNot applicableNot applicableCanada
M.O.S. 10 Syrup 10mg/mlsyrup10 mgoralValeant Canada Lp Valeant Canada S.E.C.1985-12-312014-07-30Canada
M.O.S. 10 Tablets 10mgtablet10 mgoralValeant Canada Lp Valeant Canada S.E.C.1986-12-312014-07-30Canada
M.O.S. 20 Concentrate 20mg/mlsyrup20 mgoralValeant Canada Lp Valeant Canada S.E.C.1985-12-312014-07-30Canada
M.O.S. SR Tablets 30mgtablet (extended-release)30 mgoralValeant Canada Lp/valeant Canada s.e.c.1988-12-312016-07-08Canada
M.O.S. SR Tablets 60mgtablet (extended-release)60 mgoralValeant Canada Lp/valeant Canada s.e.c.1988-12-312016-07-08Canada
M.O.S. Sulphate 10mg Tabtablet10 mgoralValeant Canada Lp/valeant Canada s.e.c.1993-12-312016-07-08Canada
M.O.S. Sulphate 25mg Tabtablet25 mgoralValeant Canada Lp/valeant Canada s.e.c.1993-12-312016-07-08Canada
M.O.S. Sulphate 50mg Tabtablet50 mgoralValeant Canada Lp/valeant Canada s.e.c.1993-12-312016-07-08Canada
M.O.S. Sulphate 5mg Tabtablet5 mgoralValeant Canada Lp/valeant Canada s.e.c.1993-12-312016-07-08Canada
M.O.S. Syrup 1.0 mg/mlsyrup1 mgoralValeant Canada Lp Valeant Canada S.E.C.1980-12-312014-07-30Canada
M.O.S. Syrup 5mg/mlsyrup5 mgoralValeant Canada Lp Valeant Canada S.E.C.1981-12-312014-07-30Canada
M.O.S.- 10suppository10 mgrectalValeant Canada Lp Valeant Canada S.E.C.1984-12-312014-07-30Canada
M.O.S.- 20suppository20 mgrectalValeant Canada Lp Valeant Canada S.E.C.1984-12-312014-07-30Canada
M.O.S.- 30suppository30 mgrectalValeant Canada Lp Valeant Canada S.E.C.1985-12-312014-07-30Canada
M.O.S.-20 Tab 20mgtablet20 mgoralValeant Canada Lp Valeant Canada S.E.C.1986-12-312014-07-30Canada
M.O.S.-40 Tab 40mgtablet40 mgoralValeant Canada Lp Valeant Canada S.E.C.1986-12-312014-07-30Canada
M.O.S.-50 Concentrate Liq 50mg/mlsyrup50 mgoralValeant Canada Lp Valeant Canada S.E.C.1986-12-312014-07-30Canada
M.O.S.-60 Tab 60mgtablet60 mgoralValeant Canada Lp Valeant Canada S.E.C.1986-12-312014-07-30Canada
Morphabondtablet, extended release15 mg/1oralInspirion Delivery Technologies, Llc2016-04-02Not applicableUs
Morphabondtablet, extended release100 mg/1oralInspirion Delivery Technologies, Llc2016-04-02Not applicableUs
Morphabondtablet, extended release60 mg/1oralInspirion Delivery Technologies, Llc2016-04-02Not applicableUs
Morphabondtablet, extended release30 mg/1oralInspirion Delivery Technologies, Llc2016-04-02Not applicableUs
Morphine Extra Forte Injection 50mg/ml USPsolution50 mgintramuscular; intravenous; subcutaneousHospira Healthcare Corporation1990-12-31Not applicableCanada
Morphine Forte Injection 25mg/ml USPsolution25 mgintramuscular; intravenous; subcutaneousHospira Healthcare Corporation1990-12-31Not applicableCanada
Morphine Hp 25 - 25mg/mlsolution25 mgintramuscular; intravenous; subcutaneousSandoz Canada Incorporated1986-12-31Not applicableCanada
Morphine Hp 50 - 50mg/ml USPsolution50 mgintramuscular; intravenous; subcutaneousSandoz Canada Incorporated1987-12-31Not applicableCanada
Morphine Lp Epiduralsolution0.5 mgintravenous; subcutaneous; epiduralSandoz Canada Incorporated1993-12-31Not applicableCanada
Morphine Lp Epiduralsolution1 mgintravenous; subcutaneous; epiduralSandoz Canada Incorporated1993-12-31Not applicableCanada
Morphine SRtablet (extended-release)200 mgoralSanis Health Inc2011-03-012014-08-01Canada
Morphine SRtablet (extended-release)15 mgoralSanis Health Inc2011-03-01Not applicableCanada
Morphine SRtablet (extended-release)30 mgoralSanis Health Inc2011-03-01Not applicableCanada
Morphine SRtablet (extended-release)100 mgoralSanis Health Inc2011-03-012014-08-01Canada
Morphine SRtablet (extended-release)60 mgoralSanis Health Inc2011-03-02Not applicableCanada
Morphine Sulfatetablet30 mg/1oralSTAT Rx USA LLC2008-03-17Not applicableUs
Morphine Sulfatecapsule, extended release50 mg/1oralPar Pharmaceutical Inc.2012-11-09Not applicableUs
Morphine Sulfatetablet15 mg/1oralH.J. Harkins Company, Inc.2008-03-17Not applicableUs
Morphine Sulfatesolution10 mg/5mLoralPrecision Dose Inc.2016-02-29Not applicableUs
Morphine Sulfatecapsule, extended release20 mg/1oralActavis Elizabeth LLC2011-11-11Not applicableUs
Morphine Sulfatesolution, concentrate100 mg/5mLoralLannett Company, Inc.2011-06-23Not applicableUs
Morphine Sulfatesolution10 mg/5mLoralPhysicians Total Care, Inc.2005-09-12Not applicableUs
Morphine Sulfatetablet15 mg/1oralRoxane Laboratories, Inc2008-03-17Not applicableUs
Morphine Sulfateinjection, solution4 mg/mLintravenousHospira, Inc.2011-11-14Not applicableUs
Morphine Sulfateinjection, solution8 mg/mLintramuscular; intravenousBD Rx Inc.2013-02-14Not applicableUs
Morphine Sulfatecapsule, extended release80 mg/1oralActavis Elizabeth LLC2011-11-11Not applicableUs
Morphine Sulfatetablet15 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2012-03-19Not applicableUs
Morphine Sulfatesolution100 mg/5mLoralPrecision Dose Inc.2014-06-04Not applicableUs
Morphine Sulfatesolution100 mg/5mLoralRoxane Laboratories, Inc2011-01-25Not applicableUs
Morphine Sulfateinjection, solution.5 mg/mLintravenousHospira, Inc.1992-10-30Not applicableUs
Morphine Sulfatetablet30 mg/1oralbryant ranch prepack2008-03-17Not applicableUs
Morphine Sulfatecapsule, extended release60 mg/1oralPar Pharmaceutical Inc.2012-11-09Not applicableUs
Morphine Sulfatetablet30 mg/1oralH.J. Harkins Company, Inc.2008-03-17Not applicableUs
Morphine Sulfateinjection, solution2 mg/mLintramuscular; intravenousBD Rx Inc.2013-02-14Not applicableUs
Morphine Sulfatecapsule, extended release30 mg/1oralActavis Elizabeth LLC2011-11-11Not applicableUs
Morphine Sulfatetablet30 mg/1oralRoxane Laboratories, Inc2008-03-17Not applicableUs
Morphine Sulfateinjection, solution8 mg/mLintravenousHospira, Inc.2011-11-14Not applicableUs
Morphine Sulfateinjection, solution10 mg/mLintramuscular; intravenousBD Rx Inc.2013-02-14Not applicableUs
Morphine Sulfatecapsule, extended release100 mg/1oralActavis Elizabeth LLC2011-11-11Not applicableUs
Morphine Sulfateinjection10 mg/.7mLintramuscularMeridian Medical Technologies, Inc.1990-07-12Not applicableUs
Morphine Sulfatetablet30 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2011-12-13Not applicableUs
Morphine Sulfatesolution100 mg/5mLoralRoxane Laboratories, Inc2011-01-25Not applicableUs
Morphine Sulfateinjection, solution1 mg/mLintravenousHospira, Inc.1992-10-30Not applicableUs
Morphine Sulfatecapsule, extended release20 mg/1oralPar Pharmaceutical Inc.2012-11-09Not applicableUs
Morphine Sulfatetablet15 mg/1oralbryant ranch prepack2008-03-17Not applicableUs
Morphine Sulfatecapsule, extended release50 mg/1oralActavis Elizabeth LLC2011-11-11Not applicableUs
Morphine Sulfatesolution10 mg/5mLoralAtlantic Biologicals Corps2008-03-17Not applicableUs
Morphine Sulfatecapsule, extended release80 mg/1oralPar Pharmaceutical Inc.2012-11-09Not applicableUs
Morphine Sulfatetablet15 mg/1oralPhysicians Total Care, Inc.2008-01-07Not applicableUs
Morphine Sulfatetablet30 mg/1oralDispensing Solutions, Inc.2008-03-17Not applicableUs
Morphine Sulfateinjection, solution4 mg/mLintramuscular; intravenousBD Rx Inc.2013-02-14Not applicableUs
Morphine Sulfatesolution10 mg/5mLoralRoxane Laboratories, Inc2008-03-17Not applicableUs
Morphine Sulfateinjection, solution10 mg/mLintravenousHospira, Inc.2011-11-14Not applicableUs
Morphine Sulfatecapsule, extended release200 mg/1oralActavis Elizabeth LLC2011-11-11Not applicableUs
Morphine Sulfatetablet30 mg/1oralPhysicians Total Care, Inc.2009-05-29Not applicableUs
Morphine Sulfatecapsule, extended release10 mg/1oralActavis Elizabeth LLC2011-11-11Not applicableUs
Morphine Sulfateinjection, solution5 mg/mLintravenousHospira, Inc.1992-10-30Not applicableUs
Morphine Sulfatetablet15 mg/1oralSTAT Rx USA LLC2008-03-17Not applicableUs
Morphine Sulfatecapsule, extended release30 mg/1oralPar Pharmaceutical Inc.2012-11-09Not applicableUs
Morphine Sulfatecapsule, extended release60 mg/1oralActavis Elizabeth LLC2011-11-11Not applicableUs
Morphine Sulfatecapsule, extended release100 mg/1oralPar Pharmaceutical Inc.2012-11-09Not applicableUs
Morphine Sulfatesolution100 mg/5mLoralPrecision Dose Inc.2013-08-16Not applicableUs
Morphine Sulfateinjection, solution5 mg/mLintramuscular; intravenousBD Rx Inc.2013-02-14Not applicableUs
Morphine Sulfatesolution20 mg/5mLoralRoxane Laboratories, Inc2008-03-17Not applicableUs
Morphine Sulfateinjection, solution15 mg/mLintravenousHospira, Inc.2011-11-14Not applicableUs
Morphine Sulfateinjection, solution2 mg/mLintravenousHospira, Inc.2011-11-14Not applicableUs
Morphine Sulfate Inj 10mg/ml USPliquid10 mgintramuscular; intravenous; subcutaneousSandoz Canada Incorporated1978-12-31Not applicableCanada
Morphine Sulfate Inj 15mg/ml USPliquid15 mgintramuscular; intravenous; subcutaneousSandoz Canada Incorporated1978-12-31Not applicableCanada
Morphine Sulfate Inj 1mg/ml USPsolution1 mgintravenous; subcutaneousSandoz Canada Incorporated1992-12-31Not applicableCanada
Morphine Sulfate Inj 2mg/ml USPsolution2 mgintravenous; subcutaneousSandoz Canada Incorporated1992-12-31Not applicableCanada
Morphine Sulfate Inj 5mg/ml USPsolution5 mgintravenous; subcutaneousSandoz Canada Incorporated1992-12-31Not applicableCanada
Morphine Sulfate Injection 10mg/ml USPsolution10 mgintramuscular; intravenous; subcutaneousHospira Healthcare Corporation1988-12-31Not applicableCanada
Morphine Sulfate Injection 15mg/ml USPsolution15 mgintramuscular; intravenous; subcutaneousHospira Healthcare Corporation1989-12-31Not applicableCanada
Morphine Sulfate Injection 1mg/mlsolution1 mgintravenousHospira Healthcare Corporation1986-12-31Not applicableCanada
Morphine Sulfate Injection 2mg/ml USPsolution2 mgintramuscular; intravenous; subcutaneousHospira Healthcare Corporation1989-12-31Not applicableCanada
Morphine Sulfate Injection 5mg/ml USPsolution5 mgintravenousHospira Healthcare Corporation1986-12-31Not applicableCanada
Morphine Sulfate Injection Sdzsolution10 mgintramuscular; intravenous; subcutaneousSandoz Canada Incorporated2012-10-18Not applicableCanada
Morphine Sulfate Injection Sdzsolution15 mgintramuscular; intravenous; subcutaneousSandoz Canada IncorporatedNot applicableNot applicableCanada
Morphine Sulfate Injection Sdzsolution1 mgintramuscular; intravenous; subcutaneousSandoz Canada IncorporatedNot applicableNot applicableCanada
Morphine Sulfate Injection Sdzsolution2 mgintramuscular; intravenous; subcutaneousSandoz Canada IncorporatedNot applicableNot applicableCanada
Morphine Sulfate Injection USPliquid2 mgintramuscular; intravenous; subcutaneousSandoz Canada Incorporated2000-12-12Not applicableCanada
Morphine Sulphate Inj 1mg/ml BPliquid1 mgintravenous; subcutaneousDavid Bull Laboratories (Canada) Inc.1993-12-311998-08-13Canada
Morphine Sulphate Injection 1mg/mlliquid1 mgintravenous; subcutaneousHospira Healthcare Corporation1997-09-04Not applicableCanada
Morphine Sulphate Injection 2mg/mlliquid2 mgintravenous; subcutaneousHospira Healthcare Corporation1997-09-04Not applicableCanada
Morphine Sulphate Injection 50mg/mlliquid50 mgintramuscular; intravenous; subcutaneousHospira Healthcare Corporation1997-09-11Not applicableCanada
Morphine Sulphate Injection B.P. 25mg/mlliquid25 mgintramuscular; intravenous; subcutaneousDavid Bull Laboratories (Canada) Inc.1994-12-311997-08-14Canada
Morphine Sulphate Injection B.P. 50mg/mlliquid50 mgintramuscular; intravenous; subcutaneousDavid Bull Laboratories (Canada) Inc.1994-12-311998-08-13Canada
Morphine Sulphate Injection Bp 2mg/mlliquid2 mgintravenous; subcutaneousDavid Bull Laboratories (Canada) Inc.1993-12-311998-08-13Canada
Morphine Sulphate Injection, USPliquid25 mgintravenousInternational Medication Systems Ltd.1993-12-311997-08-15Canada
Morphine Sulphate Injection, USP Liq50mg/mlliquid50 mgintravenousInternational Medication Systems Ltd.1993-12-311997-08-15Canada
Morphine Sulphate Injection,usp Liq 1.1mg/mlliquid1.1 mgintravenous; refer (see dosage form)International Medication Systems Ltd.1993-12-311997-08-15Canada
Morphine-epd Injection 0.5mg/ml USPsolution0.5 mgepiduralHospira Healthcare Corporation1992-12-31Not applicableCanada
Morphine-epd Injection 1mg/ml USPsolution1 mgepiduralHospira Healthcare Corporation1992-12-31Not applicableCanada
Ms Contintablet, film coated, extended release30 mg/1oralPurdue Pharma LP1987-07-01Not applicableUs
Ms Contintablet, film coated, extended release15 mg/1oralLake Erie Medical DBA Quality Care Products LLC2011-01-31Not applicableUs
Ms Contintablet, film coated, extended release60 mg/1oralCardinal Health1987-07-01Not applicableUs
Ms Contintablet, film coated, extended release60 mg/1oralPurdue Pharma LP1987-07-01Not applicableUs
Ms Contintablet, film coated, extended release100 mg/1oralCardinal Health1987-07-01Not applicableUs
Ms Contintablet, film coated, extended release100 mg/1oralPurdue Pharma LP1987-07-01Not applicableUs
Ms Contintablet, film coated, extended release15 mg/1oralPurdue Pharma LP1987-07-01Not applicableUs
Ms Contintablet, film coated, extended release200 mg/1oralPurdue Pharma LP1987-07-01Not applicableUs
Ms Contintablet, film coated, extended release30 mg/1oralCardinal Health1987-07-01Not applicableUs
Ms Contin CRtablet, film coated, extended release60 mg/1oralSTAT Rx USA LLC1987-07-01Not applicableUs
Ms Contin Srt 100mgtablet (extended-release)100 mgoralPurdue Pharma1993-12-31Not applicableCanada
Ms Contin Srt 15mgtablet (extended-release)15 mgoralPurdue Pharma1993-12-31Not applicableCanada
Ms Contin Srt 200mgtablet (extended-release)200 mgoralPurdue Pharma1993-12-31Not applicableCanada
Ms Contin Srt 30mgtablet (extended-release)30 mgoralPurdue Pharma1993-12-31Not applicableCanada
Ms Contin Srt 60mgtablet (extended-release)60 mgoralPurdue Pharma1993-12-31Not applicableCanada
Ms Contin Suppositories - 30mgsuppository (sustained-release)30 mgrectalPurdue Pharma1995-12-312003-07-29Canada
Ms Contin Suppositories - 100mgsuppository (sustained-release)100 mgrectalPurdue Pharma1995-12-312003-07-29Canada
Ms Contin Suppositories - 200mgsuppository (sustained-release)200 mgrectalPurdue Pharma1995-12-312003-07-29Canada
Ms Contin Suppositories - 60mgsuppository (sustained-release)60 mgrectalPurdue Pharma1995-12-312003-07-29Canada
Ms Contin Tabletstablet (extended-release)5 mgoralPurdue PharmaNot applicableNot applicableCanada
Ms Contin XL Capsulescapsule (sustained-release)90 mgoralPurdue PharmaNot applicableNot applicableCanada
Ms Contin XL Capsulescapsule (sustained-release)120 mgoralPurdue PharmaNot applicableNot applicableCanada
Ms Contin XL Capsulescapsule (sustained-release)150 mgoralPurdue PharmaNot applicableNot applicableCanada
Ms Contin XL Capsulescapsule (sustained-release)30 mgoralPurdue PharmaNot applicableNot applicableCanada
Ms Contin XL Capsulescapsule (sustained-release)200 mgoralPurdue PharmaNot applicableNot applicableCanada
Ms Contin XL Capsulescapsule (sustained-release)60 mgoralPurdue PharmaNot applicableNot applicableCanada
Ms Ir Sup 30mgsuppository30 mgrectalPurdue Pharma1991-12-312003-07-29Canada
Ms Ir Sup 10mgsuppository10 mgrectalPurdue Pharma1991-12-312003-07-29Canada
Ms Ir Sup 20mgsuppository20 mgrectalPurdue Pharma1991-12-312003-07-29Canada
Ms Ir Tab 10mgtablet10 mgoralPurdue Pharma1993-12-31Not applicableCanada
Ms Ir Tab 20mgtablet20 mgoralPurdue Pharma1991-12-31Not applicableCanada
Ms Ir Tab 30mgtablet30 mgoralPurdue Pharma1991-12-31Not applicableCanada
Ms Ir Tab 5mgtablet5 mgoralPurdue Pharma1991-12-31Not applicableCanada
Ntp-morphine SRtablet (extended-release)100 mgoralTeva Canada LimitedNot applicableNot applicableCanada
Ntp-morphine SRtablet (extended-release)15 mgoralTeva Canada LimitedNot applicableNot applicableCanada
Ntp-morphine SRtablet (extended-release)200 mgoralTeva Canada LimitedNot applicableNot applicableCanada
Ntp-morphine SRtablet (extended-release)30 mgoralTeva Canada LimitedNot applicableNot applicableCanada
Ntp-morphine SRtablet (extended-release)60 mgoralTeva Canada LimitedNot applicableNot applicableCanada
Opium Tincturetincture10 mgoralD.C. Labs Limited1951-12-312003-07-11Canada
Oramorph SR Tablets 100mgtablet (extended-release)100 mgoralRoxane Labs, Division Of Boehringer Ingelheim1992-12-312001-07-30Canada
Oramorph SR Tablets 30mgtablet (extended-release)30 mgoralRoxane Labs, Division Of Boehringer Ingelheim1992-12-312002-07-25Canada
Oramorph SR Tablets 60mgtablet (extended-release)60 mgoralRoxane Labs, Division Of Boehringer Ingelheim1992-12-312002-07-25Canada
PMS-morphine Sulfate SR 100 mgtablet (extended-release)100 mgoralPharmascience Inc2007-12-172012-11-09Canada
PMS-morphine Sulfate SR 15 mgtablet (extended-release)15 mgoralPharmascience Inc2002-02-202012-11-09Canada
PMS-morphine Sulfate SR 200 mgtablet (extended-release)200 mgoralPharmascience Inc2007-12-172012-11-09Canada
PMS-morphine Sulfate SR 30 mgtablet (extended-release)30 mgoralPharmascience Inc2002-02-202012-11-09Canada
PMS-morphine Sulfate SR 60 mgtablet (extended-release)60 mgoralPharmascience Inc2002-02-202012-11-09Canada
Ratio-morphinesyrup1 mgoralTeva Canada Limited1984-12-31Not applicableCanada
Ratio-morphinesyrup5 mgoralTeva Canada Limited1985-12-31Not applicableCanada
Ratio-morphinesyrup20 mgoralTeva Canada Limited1986-12-31Not applicableCanada
Ratio-morphinesyrup10 mgoralTeva Canada Limited1986-12-31Not applicableCanada
Sandoz Morphine SRtablet (extended-release)60 mgoralSandoz Canada Incorporated2001-11-14Not applicableCanada
Sandoz Morphine SRtablet (extended-release)15 mgoralSandoz Canada Incorporated2001-11-14Not applicableCanada
Sandoz Morphine SRtablet (extended-release)30 mgoralSandoz Canada Incorporated2001-11-14Not applicableCanada
Statex Dps 50mg/mldrops50 mgoralPaladin Labs Inc1986-12-31Not applicableCanada
Statex Drops 20mg/mldrops20 mgoralPaladin Labs Inc1984-12-31Not applicableCanada
Statex Suppositories 20mgsuppository20 mgrectalPaladin Labs Inc1985-12-31Not applicableCanada
Statex Suppositories 30mgsuppository30 mgrectalPaladin Labs Inc1997-08-04Not applicableCanada
Statex Suppositories 5mgsuppository5 mgrectalPaladin Labs Inc1997-08-04Not applicableCanada
Statex Syrup 10mg/mlsyrup10 mgoralPaladin Labs Inc1987-12-31Not applicableCanada
Statex Syrup 1mg/mlsyrup1 mgoralPaladin Labs Inc1984-12-31Not applicableCanada
Statex Syrup 5mg/mlsyrup5 mgoralPaladin Labs Inc1984-12-31Not applicableCanada
Statex Tab 10mgtablet10 mgoralPaladin Labs Inc1985-12-31Not applicableCanada
Statex Tab 5mgtablet5 mgoralPaladin Labs Inc1985-12-31Not applicableCanada
Statex Tablet 25mgtablet25 mgoralPaladin Labs Inc1985-12-31Not applicableCanada
Statex Tablets 50mgtablet50 mgoralPaladin Labs Inc1986-12-31Not applicableCanada
Statex-suppositories 10mgsuppository10 mgrectalPaladin Labs Inc1985-12-31Not applicableCanada
Teva-morphine SRtablet (extended-release)15 mgoralTeva Canada Limited2009-03-25Not applicableCanada
Teva-morphine SRtablet (extended-release)200 mgoralTeva Canada Limited2008-04-01Not applicableCanada
Teva-morphine SRtablet (extended-release)30 mgoralTeva Canada Limited2009-03-25Not applicableCanada
Teva-morphine SRtablet (extended-release)60 mgoralTeva Canada Limited2008-04-01Not applicableCanada
Teva-morphine SRtablet (extended-release)100 mgoralTeva Canada Limited2008-04-01Not applicableCanada
Zomorphcapsule (sustained-release)120 mgoralEthypharm IncNot applicableNot applicableCanada
Zomorphcapsule (sustained-release)20 mgoralEthypharm IncNot applicableNot applicableCanada
Zomorphcapsule (sustained-release)200 mgoralEthypharm IncNot applicableNot applicableCanada
Zomorphcapsule (sustained-release)40 mgoralEthypharm IncNot applicableNot applicableCanada
Zomorphcapsule (sustained-release)60 mgoralEthypharm IncNot applicableNot applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Morphine Sulfatetablet, film coated, extended release15 mg/1oralPd Rx Pharmaceuticals, Inc.1987-05-01Not applicableUs
Morphine Sulfatetablet, film coated, extended release30 mg/1oralH.J. Harkins Company, Inc.2011-01-14Not applicableUs
Morphine Sulfatetablet, extended release100 mg/1oralQualitest Pharmaceuticals1998-10-31Not applicableUs
Morphine Sulfatetablet, extended release15 mg/1oralNovel Laboratories, Inc.2015-12-16Not applicableUs
Morphine Sulfatetablet, film coated, extended release30 mg/1oralActavis Pharma, Inc.2015-10-26Not applicableUs
Morphine Sulfateinjection, solution.5 mg/mLepidural; intrathecal; intravenousHospira, Inc.1992-09-30Not applicableUs
Morphine Sulfatetablet, film coated, extended release200 mg/1oralWatson Laboratories, Inc.1987-05-01Not applicableUs
Morphine Sulfatesolution10 mg/5mLoralTris Pharma Inc2015-05-31Not applicableUs
Morphine Sulfatecapsule, extended release30 mg/1oralUpsher Smith Laboratories, Inc.2013-06-30Not applicableUs
Morphine Sulfatecapsule, extended release60 mg/1oralPar Pharmaceutical Inc.2011-11-10Not applicableUs
Morphine Sulfatetablet, film coated, extended release30 mg/1oralEthex Corporation2010-04-22Not applicableUs
Morphine Sulfatetablet, film coated, extended release60 mg/1oralRanbaxy Pharmaceuticals Inc.2012-05-11Not applicableUs
Morphine Sulfatetablet, extended release60 mg/1oralAmerican Health Packaging2011-08-01Not applicableUs
Morphine Sulfatecapsule, extended release30 mg/1oralActavis Pharma, Inc.2014-02-04Not applicableUs
Morphine Sulfatetablet, film coated, extended release200 mg/1oralMylan Pharmaceuticals Inc.2011-10-26Not applicableUs
Morphine Sulfatecapsule, extended release60 mg/1oralWatson Laboratories, Inc.2011-11-10Not applicableUs
Morphine Sulfatesolution100 mg/5mLoralPaddock Laboratories, LLC2012-08-17Not applicableUs
Morphine Sulfateinjection8 mg/mLintravenousWest Ward Pharmaceuticals Corp.2015-06-03Not applicableUs
Morphine Sulfatesolution20 mg/mLoralSafecor Health, LLC2013-01-17Not applicableUs
Morphine Sulfatetablet, extended release100 mg/1oralPhysicians Total Care, Inc.2006-05-17Not applicableUs
Morphine Sulfatetablet, film coated, extended release15 mg/1oralRanbaxy Pharmaceuticals Inc.2012-05-11Not applicableUs
Morphine Sulfatetablet, extended release200 mg/1oralNovel Laboratories, Inc.2015-12-16Not applicableUs
Morphine Sulfatetablet, film coated, extended release15 mg/1oralMylan Pharmaceuticals Inc.2011-10-26Not applicableUs
Morphine Sulfatetablet, extended release30 mg/1oralMallinckrodt, Inc.2010-10-21Not applicableUs
Morphine Sulfatetablet, film coated, extended release30 mg/1oralWatson Laboratories, Inc.1987-05-01Not applicableUs
Morphine Sulfatecapsule, extended release100 mg/1oralUpsher Smith Laboratories, Inc.2013-06-30Not applicableUs
Morphine Sulfatetablet, extended release15 mg/1oralQualitest Pharmaceuticals1998-10-31Not applicableUs
Morphine Sulfatetablet, film coated, extended release15 mg/1oralbryant ranch prepack2011-01-14Not applicableUs
Morphine Sulfatetablet, extended release60 mg/1oralZydus Pharmaceuticals (USA) Inc.2015-07-09Not applicableUs
Morphine Sulfatecapsule, extended release45 mg/1oralActavis Pharma, Inc.2014-02-04Not applicableUs
Morphine Sulfatesolution20 mg/5mLoralQualitest Pharmaceuticals2015-10-30Not applicableUs
Morphine Sulfatetablet, film coated, extended release30 mg/1oralPd Rx Pharmaceuticals, Inc.1987-05-01Not applicableUs
Morphine Sulfatetablet, extended release30 mg/1oralPhysicians Total Care, Inc.2005-06-30Not applicableUs
Morphine Sulfatetablet, extended release200 mg/1oralQualitest Pharmaceuticals1998-10-31Not applicableUs
Morphine Sulfatetablet, extended release30 mg/1oralNovel Laboratories, Inc.2015-12-16Not applicableUs
Morphine Sulfatetablet, film coated, extended release60 mg/1oralActavis Pharma, Inc.2015-10-26Not applicableUs
Morphine Sulfateinjection, solution1 mg/mLepidural; intrathecal; intravenousHospira, Inc.1992-09-30Not applicableUs
Morphine Sulfatesolution20 mg/mLoralMallinckrodt, Inc.2011-10-03Not applicableUs
Morphine Sulfatecapsule, extended release100 mg/1oralWatson Laboratories, Inc.2011-11-10Not applicableUs
Morphine Sulfatecapsule, extended release50 mg/1oralUpsher Smith Laboratories, Inc.2013-06-30Not applicableUs
Morphine Sulfatecapsule, extended release80 mg/1oralPar Pharmaceutical Inc.2011-11-10Not applicableUs
Morphine Sulfatetablet, film coated, extended release60 mg/1oralEthex Corporation2010-04-22Not applicableUs
Morphine Sulfatetablet, extended release100 mg/1oralAmerican Health Packaging2011-08-01Not applicableUs
Morphine Sulfatecapsule, extended release60 mg/1oralActavis Pharma, Inc.2014-02-04Not applicableUs
Morphine Sulfatetablet, film coated, extended release30 mg/1oralMylan Pharmaceuticals Inc.2011-10-26Not applicableUs
Morphine Sulfatecapsule, extended release20 mg/1oralWatson Laboratories, Inc.2011-11-10Not applicableUs
Morphine Sulfateinjection10 mg/mLintravenousWest Ward Pharmaceuticals Corp.2015-06-03Not applicableUs
Morphine Sulfatecapsule, extended release20 mg/1oralPar Pharmaceutical Inc.2011-11-10Not applicableUs
Morphine Sulfatetablet, film coated, extended release30 mg/1oralRanbaxy Pharmaceuticals Inc.2012-05-11Not applicableUs
Morphine Sulfatetablet, film coated, extended release30 mg/1oralLake Erie Medical DBA Quality Care Products LLC2015-10-26Not applicableUs
Morphine Sulfatecapsule, extended release75 mg/1oralActavis Pharma, Inc.2014-02-04Not applicableUs
Morphine Sulfatetablet, extended release60 mg/1oralMallinckrodt, Inc.2010-10-21Not applicableUs
Morphine Sulfatetablet, film coated, extended release60 mg/1oralWatson Laboratories, Inc.1987-05-01Not applicableUs
Morphine Sulfatetablet, film coated, extended release15 mg/1oralSTAT Rx USA LLC2011-01-14Not applicableUs
Morphine Sulfatetablet, extended release30 mg/1oralQualitest Pharmaceuticals1998-10-31Not applicableUs
Morphine Sulfatetablet, film coated, extended release30 mg/1oralbryant ranch prepack2011-01-14Not applicableUs
Morphine Sulfatetablet, extended release100 mg/1oralZydus Pharmaceuticals (USA) Inc.2015-07-09Not applicableUs
Morphine Sulfateinjection, solution.5 mg/mLepidural; intrathecal; intravenousHospira, Inc.1988-05-11Not applicableUs
Morphine Sulfatesolution10 mg/5mLoralQualitest Pharmaceuticals2015-11-25Not applicableUs
Morphine Sulfatetablet, film coated, extended release60 mg/1oralPd Rx Pharmaceuticals, Inc.1987-05-01Not applicableUs
Morphine Sulfatetablet, extended release60 mg/1oralPhysicians Total Care, Inc.2004-04-26Not applicableUs
Morphine Sulfatetablet, film coated, extended release30 mg/1oralDIRECT RX2015-01-01Not applicableUs
Morphine Sulfatesolution10 mg/5mLoralVista Pharm Inc.2012-03-01Not applicableUs
Morphine Sulfatetablet, extended release60 mg/1oralNovel Laboratories, Inc.2015-12-16Not applicableUs
Morphine Sulfatetablet, film coated, extended release100 mg/1oralActavis Pharma, Inc.2015-10-26Not applicableUs
Morphine Sulfatetablet, extended release15 mg/1oralMallinckrodt, Inc.2010-10-21Not applicableUs
Morphine Sulfatecapsule, extended release80 mg/1oralWatson Laboratories, Inc.2011-11-10Not applicableUs
Morphine Sulfatecapsule, extended release60 mg/1oralUpsher Smith Laboratories, Inc.2013-06-30Not applicableUs
Morphine Sulfatecapsule, extended release100 mg/1oralPar Pharmaceutical Inc.2011-11-10Not applicableUs
Morphine Sulfatetablet, film coated, extended release100 mg/1oralEthex Corporation2009-01-01Not applicableUs
Morphine Sulfatetablet, film coated, extended release15 mg/1oralbryant ranch prepack2010-03-26Not applicableUs
Morphine Sulfatetablet, extended release15 mg/1oralZydus Pharmaceuticals (USA) Inc.2015-07-09Not applicableUs
Morphine Sulfatecapsule, extended release90 mg/1oralActavis Pharma, Inc.2014-02-04Not applicableUs
Morphine Sulfatetablet, film coated, extended release60 mg/1oralMylan Pharmaceuticals Inc.2011-10-26Not applicableUs
Morphine Sulfatecapsule, extended release30 mg/1oralWatson Laboratories, Inc.2011-11-10Not applicableUs
Morphine Sulfatecapsule, extended release10 mg/1oralUpsher Smith Laboratories, Inc.2013-06-30Not applicableUs
Morphine Sulfatecapsule, extended release30 mg/1oralPar Pharmaceutical Inc.2011-11-10Not applicableUs
Morphine Sulfatesolution20 mg/5mLoralCaraco Pharmaceutical Laboratories, Ltd.2012-01-31Not applicableUs
Morphine Sulfatetablet, film coated, extended release100 mg/1oralRanbaxy Pharmaceuticals Inc.2012-05-11Not applicableUs
Morphine Sulfatetablet, extended release15 mg/1oralAmerican Health Packaging2011-08-01Not applicableUs
Morphine Sulfatetablet, extended release200 mg/1oralZydus Pharmaceuticals (USA) Inc.2015-07-09Not applicableUs
Morphine Sulfatetablet, film coated, extended release15 mg/1oralActavis Pharma, Inc.2015-10-26Not applicableUs
Morphine Sulfatetablet, extended release100 mg/1oralMallinckrodt, Inc.2010-10-21Not applicableUs
Morphine Sulfatetablet, film coated, extended release100 mg/1oralWatson Laboratories, Inc.1987-05-01Not applicableUs
Morphine Sulfatesolution20 mg/mLoralTris Pharma Inc2015-09-21Not applicableUs
Morphine Sulfatetablet, film coated, extended release15 mg/1oralH.J. Harkins Company, Inc.2011-01-14Not applicableUs
Morphine Sulfatetablet, extended release60 mg/1oralQualitest Pharmaceuticals1998-10-31Not applicableUs
Morphine Sulfateinjection, solution1 mg/mLepidural; intrathecal; intravenousHospira, Inc.1988-05-11Not applicableUs
Morphine Sulfateinjection4 mg/mLintravenousWest Ward Pharmaceuticals Corp.2015-06-03Not applicableUs
Morphine Sulfatetablet, film coated, extended release100 mg/1oralPd Rx Pharmaceuticals, Inc.1987-05-01Not applicableUs
Morphine Sulfatetablet, extended release15 mg/1oralPhysicians Total Care, Inc.2004-08-10Not applicableUs
Morphine Sulfatetablet, film coated, extended release15 mg/1oralDIRECT RX2015-01-01Not applicableUs
Morphine Sulfatesolution20 mg/5mLoralVista Pharm Inc.2012-03-01Not applicableUs
Morphine Sulfatetablet, extended release100 mg/1oralNovel Laboratories, Inc.2015-12-16Not applicableUs
Morphine Sulfatetablet, film coated, extended release200 mg/1oralActavis Pharma, Inc.2015-10-26Not applicableUs
Morphine Sulfatetablet, extended release200 mg/1oralMallinckrodt, Inc.2010-10-21Not applicableUs
Morphine Sulfatetablet, film coated, extended release15 mg/1oralWatson Laboratories, Inc.1987-05-01Not applicableUs
Morphine Sulfatecapsule, extended release80 mg/1oralUpsher Smith Laboratories, Inc.2013-06-30Not applicableUs
Morphine Sulfatetablet, film coated, extended release200 mg/1oralEthex Corporation2009-01-01Not applicableUs
Morphine Sulfatetablet, extended release30 mg/1oralZydus Pharmaceuticals (USA) Inc.2015-07-09Not applicableUs
Morphine Sulfatecapsule, extended release120 mg/1oralActavis Pharma, Inc.2014-02-04Not applicableUs
Morphine Sulfatetablet, film coated, extended release200 mg/1oralRanbaxy Pharmaceuticals Inc.2012-05-11Not applicableUs
Morphine Sulfatetablet, extended release30 mg/1oralAmerican Health Packaging2011-08-01Not applicableUs
Morphine Sulfatetablet, film coated, extended release100 mg/1oralMylan Pharmaceuticals Inc.2011-10-26Not applicableUs
Morphine Sulfatecapsule, extended release50 mg/1oralWatson Laboratories, Inc.2011-11-10Not applicableUs
Morphine Sulfatecapsule, extended release20 mg/1oralUpsher Smith Laboratories, Inc.2013-06-30Not applicableUs
Morphine Sulfatecapsule, extended release50 mg/1oralPar Pharmaceutical Inc.2011-11-10Not applicableUs
Morphine Sulfatetablet, film coated, extended release15 mg/1oralEthex Corporation2009-12-03Not applicableUs
Morphine Sulfate ERtablet30 mg/1oralLake Erie Medical DBA Quality Care Products LLC2010-04-07Not applicableUs
Morphine Sulfate Extended Releasetablet, film coated, extended release60 mg/1oralbryant ranch prepack2011-01-14Not applicableUs
Morphine Sulfate Extended Releasetablet, film coated, extended release15 mg/1oralLake Erie Medical DBA Quality Care Products LLC2011-01-14Not applicableUs
Morphine Sulfate Extended Releasetablet, film coated, extended release15 mg/1oralAmerican Health Packaging2013-06-21Not applicableUs
Morphine Sulfate Extended Releasetablet, film coated, extended release60 mg/1oralRhodes Pharmaceuticals L. P.2011-01-14Not applicableUs
Morphine Sulfate Extended Releasetablet, film coated, extended release200 mg/1oralbryant ranch prepack2011-01-14Not applicableUs
Morphine Sulfate Extended Releasetablet, film coated, extended release200 mg/1oralLake Erie Medical DBA Quality Care Products LLC2011-01-14Not applicableUs
Morphine Sulfate Extended Releasetablet, film coated, extended release30 mg/1oralAmerican Health Packaging2013-06-21Not applicableUs
Morphine Sulfate Extended Releasetablet, film coated, extended release100 mg/1oralRhodes Pharmaceuticals L. P.2011-01-14Not applicableUs
Morphine Sulfate Extended Releasetablet60 mg/1oralLake Erie Medical DBA Quality Care Products LLC2010-08-19Not applicableUs
Morphine Sulfate Extended Releasetablet, film coated, extended release15 mg/1oralRhodes Pharmaceuticals L. P.2011-01-14Not applicableUs
Morphine Sulfate Extended Releasetablet, film coated, extended release30 mg/1oralLake Erie Medical DBA Quality Care Products LLC2011-01-14Not applicableUs
Morphine Sulfate Extended Releasetablet, film coated, extended release100 mg/1oralbryant ranch prepack2011-01-14Not applicableUs
Morphine Sulfate Extended Releasetablet, film coated, extended release200 mg/1oralRhodes Pharmaceuticals L. P.2011-01-14Not applicableUs
Morphine Sulfate Extended Releasetablet, film coated, extended release60 mg/1oralLake Erie Medical DBA Quality Care Products LLC2011-01-14Not applicableUs
Morphine Sulfate Extended Releasetablet, film coated, extended release30 mg/1oralRhodes Pharmaceuticals L. P.2011-01-14Not applicableUs
Morphine Sulfate Extended Releasetablet, extended release15 mg/1oral; oralLake Erie Medical DBA Quality Care Products LLC2010-09-17Not applicableUs
Morphine Sulfate Extended Releasetablet30 mg/1oralbryant ranch prepack2010-03-18Not applicableUs
Morphine Sulfate Extended Releasetablet, film coated, extended release100 mg/1oralLake Erie Medical DBA Quality Care Products LLC2011-01-14Not applicableUs
Morphine Sulfate Extended-releasetablet, extended release30 mg/1oralSTAT Rx USA LLC2010-10-21Not applicableUs
Morphine Sulfate Extended-releasetablet100 mg/1oralLake Erie Medical Surgical & Supply DBA Quality Care Products LLC2011-07-28Not applicableUs
Morphine Sulfate Extended-releasetablet, extended release15 mg/1oralSTAT Rx USA LLC2010-10-21Not applicableUs
Morphine Sulfate Extended-releasetablet60 mg/1oralbryant ranch prepack2010-10-21Not applicableUs
Morphine Sulfate Extended-releasetablet200 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2012-03-20Not applicableUs
Morphine Sulfate Oral Solutionsolution10 mg/5mLoralCaraco Pharmaceutical Laboratories, Ltd.2012-01-31Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Morphine Sulfateinjection, solution.5 mg/mLintrathecal; intravenousCantrell Drug Company2012-01-23Not applicableUs
Morphine Sulfatesuppository5 mg/1rectalPaddock Laboratories, LLC1990-09-01Not applicableUs
Morphine Sulfateinjection5 mg/mLintramuscular; intravenous; subcutaneousWest Ward Pharmaceutical Corp.1971-01-01Not applicableUs
Morphine Sulfateinjection15 mg/mLintramuscular; intravenous; subcutaneousBaxter Healthcare Corporation2010-05-262015-12-29Us
Morphine Sulfateinjection10 mg/mLintramuscular; intravenous; subcutaneousWest Ward Pharmaceutical Corp.1971-01-01Not applicableUs
Morphine Sulfateinjection1 mg/mLintravenousInternational Medication Systems, Limited1987-03-27Not applicableUs
Morphine Sulfateinjection, solution25 mg/mLintravenousHospira, Inc.1991-04-11Not applicableUs
Morphine Sulfateinjection, solution1 mg/mLintravenousCantrell Drug Company2013-09-09Not applicableUs
Morphine Sulfatesuppository10 mg/1rectalPaddock Laboratories, LLC1990-09-01Not applicableUs
Morphine Sulfateinjection, solution, concentrate50 mg/mLintravenousHospira, Inc.1996-03-14Not applicableUs
Morphine Sulfateinjection8 mg/mLintramuscular; intravenous; subcutaneousWest Ward Pharmaceutical Corp.1971-01-01Not applicableUs
Morphine Sulfateinjection5 mg/mLintramuscular; intravenous; subcutaneousBaxter Healthcare Corporation2010-05-262015-12-29Us
Morphine Sulfateinjection10 mg/mLintramuscular; intravenous; subcutaneousWest Ward Pharmaceutical Corp.1971-01-01Not applicableUs
Morphine Sulfateinjection, solution1 mg/mLintravenousCantrell Drug Company2013-05-01Not applicableUs
Morphine Sulfateinjection, solution30 mg/30mLintravenous; subcutaneousAmphastar Pharmaceuticals, Inc.1987-03-27Not applicableUs
Morphine Sulfatesuppository20 mg/1rectalPaddock Laboratories, LLC1990-09-01Not applicableUs
Morphine Sulfateinjection, solution2 mg/mLepidural; intramuscular; intrathecal; intravenousCantrell Drug Company2012-02-22Not applicableUs
Morphine Sulfateinjection, solution, concentrate25 mg/mLintravenousHospira, Inc.1996-03-14Not applicableUs
Morphine Sulfateinjection8 mg/mLintramuscular; intravenous; subcutaneousBaxter Healthcare Corporation2010-05-262015-12-29Us
Morphine Sulfateinjection15 mg/mLintramuscular; intravenous; subcutaneousWest Ward Pharmaceutical Corp.1971-01-01Not applicableUs
Morphine Sulfateinjection, solution5 mg/mLintravenousCantrell Drug Company2013-10-25Not applicableUs
Morphine Sulfateinjection, solution10 mg/10mLintravenous; subcutaneousAmphastar Pharmaceuticals, Inc.2000-08-11Not applicableUs
Morphine Sulfatesuppository30 mg/1rectalPaddock Laboratories, LLC1990-09-01Not applicableUs
Morphine Sulfateinjection, solution25 mg/mLintravenousHospira, Inc.1991-04-11Not applicableUs
Morphine Sulfateinjection10 mg/mLintramuscular; intravenous; subcutaneousBaxter Healthcare Corporation2010-05-262015-12-29Us
Morphine Sulfateinjection15 mg/mLintramuscular; intravenous; subcutaneousWest Ward Pharmaceutical Corp.1971-01-01Not applicableUs
Opium Tinctureliquid2 mg/5mLoralHi Tech Pharmacal Co., Inc.2012-08-06Not applicableUs
Opium Tincture Deodorizedsolution10 mg/mLoralValeant Pharmaceuticals North America LLC2008-09-17Not applicableUs
Opium Tincture Deodorizedtincture10 mg/mLoralEdenbridge Pharmaceuticals, LLC2010-07-15Not applicableUs
Opium Tincture Deodorizedsolution1 g/100mLoralANI Pharmaceuticals, Inc.2011-02-25Not applicableUs
Opium Tincture Deodorizedsolution10 mg/mLoralMarathon Pharmaceuticals, LLC2008-09-17Not applicableUs
International Brands
NameCompany
KapanolNot Available
MSIRNot Available
OramorphNot Available
RoxanolNot Available
Brand mixtures
NameLabellerIngredients
EmbedaSTAT Rx USA LLC
Salts
Name/CASStructureProperties
Morphine hydrochloride
ThumbNot applicableDBSALT001753
Morphine sulfate
Thumb
  • InChI Key: USAHOPJHPJHUNS-IFCNUISUSA-N
  • Monoisotopic Mass: 668.2403662
  • Average Mass: 668.754
DBSALT000122
Categories
UNII76I7G6D29C
CAS number57-27-2
WeightAverage: 285.3377
Monoisotopic: 285.136493479
Chemical FormulaC17H19NO3
InChI KeyInChIKey=BQJCRHHNABKAKU-KBQPJGBKSA-N
InChI
InChI=1S/C17H19NO3/c1-18-7-6-17-10-3-5-13(20)16(17)21-15-12(19)4-2-9(14(15)17)8-11(10)18/h2-5,10-11,13,16,19-20H,6-8H2,1H3/t10-,11+,13-,16-,17-/m0/s1
IUPAC Name
(1S,5R,13R,14S,17R)-4-methyl-12-oxa-4-azapentacyclo[9.6.1.0¹,¹³.0⁵,¹⁷.0⁷,¹⁸]octadeca-7(18),8,10,15-tetraene-10,14-diol
SMILES
[H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])C=C[C@@H]2O
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as morphinans. These are polycyclic compounds with a four-ring skeleton with three condensed six-member rings forming a partially hydrogenated phenanthrene moiety, one of which is aromatic while the two others are alicyclic.
KingdomOrganic compounds
Super ClassAlkaloids and derivatives
ClassMorphinans
Sub ClassNot Available
Direct ParentMorphinans
Alternative Parents
Substituents
  • Morphinan
  • Benzylisoquinoline
  • Phenanthrene
  • Tetralin
  • Benzofuran
  • Aralkylamine
  • Alkyl aryl ether
  • Benzenoid
  • Piperidine
  • Tertiary aliphatic amine
  • Tertiary amine
  • Secondary alcohol
  • Oxacycle
  • Azacycle
  • Organoheterocyclic compound
  • Ether
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Amine
  • Alcohol
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationFor the relief and treatment of severe pain.
PharmacodynamicsMorphine is a narcotic pain management agent indicated for the relief of pain in patients who require opioid analgesics for more than a few days. Morphine interacts predominantly with the opioid mu-receptor. These mu-binding sites are discretely distributed in the human brain, with high densities in the posterior amygdala, hypothalamus, thalamus, nucleus caudatus, putamen, and certain cortical areas. They are also found on the terminal axons of primary afferents within laminae I and II (substantia gelatinosa) of the spinal cord and in the spinal nucleus of the trigeminal nerve. In clinical settings, morphine exerts its principal pharmacological effect on the central nervous system and gastrointestinal tract. Its primary actions of therapeutic value are analgesia and sedation. Morphine appears to increase the patient's tolerance for pain and to decrease discomfort, although the presence of the pain itself may still be recognized. In addition to analgesia, alterations in mood, euphoria and dysphoria, and drowsiness commonly occur. Opioids also produce respiratory depression by direct action on brain stem respiratory centers.
Mechanism of actionThe precise mechanism of the analgesic action of morphine is unknown. However, specific CNS opiate receptors have been identified and likely play a role in the expression of analgesic effects. Morphine first acts on the mu-opioid receptors. The mechanism of respiratory depression involves a reduction in the responsiveness of the brain stem respiratory centers to increases in carbon dioxide tension and to electrical stimulation. It has been shown that morphine binds to and inhibits GABA inhibitory interneurons. These interneurons normally inhibit the descending pain inhibition pathway. So, without the inhibitory signals, pain modulation can proceed downstream.
Related Articles
AbsorptionBioavailability is approximately 30%.
Volume of distribution
  • 1 to 6 L/kg
Protein binding30-40%
Metabolism

Primarily hepatic (90%), converted to dihydromorphinone and normorphine. Also converted to morphine-3-glucuronide (M3G) and morphine-6-glucuronide. Virtually all morphine is converted to glucuronide metabolites; only a small fraction (less than 5%) of absorbed morphine is demethylated.

SubstrateEnzymesProduct
Morphine
morphine-6-glucuronideDetails
Morphine
morphine-3-glucuronideDetails
Morphine
Not Available
NormorphineDetails
Route of eliminationA small amount of glucuronide conjugates are excreted in bile, with minor enterohepatic recycling. Seven to 10% of administered morphine sulfate is excreted in the feces.
Half life2-4 hours
Clearance
  • 20 – 30 mL/min/kg [Adult]
  • 1852 +/- 116 mL/min [Chinese]
  • 1495 +/- 80 mL/min [Caucasian]
ToxicityLD50 = 461 mg/kg (rat, oral), 600 mg/kg (mouse, oral). Human lethal dose by ingestion is 120-250 mg of morphine sulfate. Symptoms of overdose include cold, clammy skin, flaccid muscles, fluid in the lungs, lowered blood pressure, "pinpoint" or dilated pupils, sleepiness leading to stupor and coma, slowed breathing, and slow pulse rate.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Codeine Action PathwayDrug actionSMP00405
Heroin Action PathwayDrug actionSMP00407
Heroin Metabolism PathwayDrug metabolismSMP00623
Morphine Action PathwayDrug actionSMP00406
Codeine Metabolism PathwayDrug metabolismSMP00621
Morphine Metabolism PathwayDrug metabolismSMP00622
SNP Mediated Effects
Interacting Gene/EnzymeSNP RS IDAllele nameDefining changeEffectReference(s)
Multidrug resistance protein 1
Gene symbol: ABCB1
UniProt: P08183
rs1045642 Not AvailableT AlleleBetter response to pain relief drugs17898703
Mu-type opioid receptor
Gene symbol: OPRM1
UniProt: P35372
rs1799971 Not AvailableA AlleleBetter response to pain relief drugs17898703
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9971
Blood Brain Barrier+0.9882
Caco-2 permeable+0.8867
P-glycoprotein substrateSubstrate0.8787
P-glycoprotein inhibitor INon-inhibitor0.8782
P-glycoprotein inhibitor IINon-inhibitor0.956
Renal organic cation transporterInhibitor0.6221
CYP450 2C9 substrateNon-substrate0.7451
CYP450 2D6 substrateSubstrate0.8919
CYP450 3A4 substrateSubstrate0.7375
CYP450 1A2 substrateNon-inhibitor0.5191
CYP450 2C9 inhibitorNon-inhibitor0.9046
CYP450 2D6 inhibitorNon-inhibitor0.647
CYP450 2C19 inhibitorNon-inhibitor0.8155
CYP450 3A4 inhibitorNon-inhibitor0.9176
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7503
Ames testNon AMES toxic0.9132
CarcinogenicityNon-carcinogens0.9634
BiodegradationNot ready biodegradable0.9944
Rat acute toxicity2.8989 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8367
hERG inhibition (predictor II)Non-inhibitor0.874
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • King pharmaceuticals inc
  • Actavis elizabeth llc
  • Ekr therapeutics inc
  • App pharmaceuticals llc
  • Baxter healthcare corp anesthesia and critical care
  • Hospira inc
  • Mallinckrodt chemical inc
  • Meridian medical technologies inc
  • Watson laboratories inc
  • Roxane laboratories inc
  • Clonmel healthcare ltd
  • Endo pharmaceuticals inc
  • Kv pharmaceutical co
  • Mallinckrodt inc
  • Purdue pharma lp
  • Xanodyne pharmaceutics inc
  • Actavis
Packagers
Dosage forms
FormRouteStrength
Capsule, coated, extended releaseoral60 mg/1
Injectionepidural; intrathecal; intravenous.5 mg/mL
Injectionepidural; intrathecal; intravenous1 mg/mL
Capsule, extended releaseoral
Injection, solutionepidural; intrathecal10 mg/mL
Injection, solutionepidural; intrathecal25 mg/mL
Capsule, extended releaseoral130 mg/1
Capsule, extended releaseoral150 mg/1
Capsule, extended releaseoral40 mg/1
Capsule, extended releaseoral70 mg/1
Capsule (sustained-release)oral10 mg
Capsule (sustained-release)oral100 mg
Capsule (sustained-release)oral50 mg
Capsuleoral20 mg/1
Capsule (extended release)oral10 mg
Capsule (extended release)oral100 mg
Capsule (extended release)oral15 mg
Capsule (extended release)oral200 mg
Capsule (extended release)oral30 mg
Capsule (extended release)oral60 mg
Capsule (immediate release)oral10 mg
Capsule (immediate release)oral20 mg
Capsule (immediate release)oral30 mg
Capsule (immediate release)oral5 mg
Tabletoral40 mg
Syruporal50 mg
Tabletoral60 mg
Solutionintramuscular; intravenous; subcutaneous50 mg
Solutionintramuscular; intravenous; subcutaneous25 mg
Solutionintravenous; subcutaneous; epidural0.5 mg
Solutionintravenous; subcutaneous; epidural1 mg
Capsule, extended releaseoral10 mg/1
Capsule, extended releaseoral100 mg/1
Capsule, extended releaseoral120 mg/1
Capsule, extended releaseoral20 mg/1
Capsule, extended releaseoral200 mg/1
Capsule, extended releaseoral30 mg/1
Capsule, extended releaseoral45 mg/1
Capsule, extended releaseoral50 mg/1
Capsule, extended releaseoral60 mg/1
Capsule, extended releaseoral75 mg/1
Capsule, extended releaseoral80 mg/1
Capsule, extended releaseoral90 mg/1
Injectionintramuscular10 mg/.7mL
Injectionintramuscular; intravenous; subcutaneous10 mg/mL
Injectionintramuscular; intravenous; subcutaneous15 mg/mL
Injectionintramuscular; intravenous; subcutaneous5 mg/mL
Injectionintramuscular; intravenous; subcutaneous8 mg/mL
Injectionintravenous1 mg/mL
Injectionintravenous10 mg/mL
Injectionintravenous4 mg/mL
Injectionintravenous8 mg/mL
Injection, solutionepidural; intramuscular; intrathecal; intravenous2 mg/mL
Injection, solutionepidural; intrathecal; intravenous.5 mg/mL
Injection, solutionepidural; intrathecal; intravenous1 mg/mL
Injection, solutionintramuscular; intravenous10 mg/mL
Injection, solutionintramuscular; intravenous2 mg/mL
Injection, solutionintramuscular; intravenous4 mg/mL
Injection, solutionintramuscular; intravenous5 mg/mL
Injection, solutionintramuscular; intravenous8 mg/mL
Injection, solutionintrathecal; intravenous.5 mg/mL
Injection, solutionintravenous.5 mg/mL
Injection, solutionintravenous1 mg/mL
Injection, solutionintravenous10 mg/mL
Injection, solutionintravenous15 mg/mL
Injection, solutionintravenous2 mg/mL
Injection, solutionintravenous25 mg/mL
Injection, solutionintravenous4 mg/mL
Injection, solutionintravenous5 mg/mL
Injection, solutionintravenous8 mg/mL
Injection, solutionintravenous; subcutaneous10 mg/10mL
Injection, solutionintravenous; subcutaneous30 mg/30mL
Injection, solution, concentrateintravenous25 mg/mL
Injection, solution, concentrateintravenous50 mg/mL
Solutionoral10 mg/5mL
Solutionoral100 mg/5mL
Solutionoral20 mg/5mL
Solutionoral20 mg/mL
Solution, concentrateoral100 mg/5mL
Suppositoryrectal10 mg/1
Suppositoryrectal20 mg/1
Suppositoryrectal30 mg/1
Suppositoryrectal5 mg/1
Tabletoral15 mg/1
Tabletoral30 mg/1
Tablet, extended releaseoral100 mg/1
Tablet, extended releaseoral15 mg/1
Tablet, extended releaseoral200 mg/1
Tablet, extended releaseoral30 mg/1
Tablet, extended releaseoral60 mg/1
Tablet, film coated, extended releaseoral100 mg/1
Tablet, film coated, extended releaseoral15 mg/1
Tablet, film coated, extended releaseoral200 mg/1
Tablet, film coated, extended releaseoral30 mg/1
Tablet, film coated, extended releaseoral60 mg/1
Tabletoral60 mg/1
Tablet, extended releaseoral; oral15 mg/1
Tabletoral100 mg/1
Tabletoral200 mg/1
Liquidintramuscular; intravenous; subcutaneous10 mg
Liquidintramuscular; intravenous; subcutaneous15 mg
Solutionintravenous; subcutaneous1 mg
Solutionintravenous; subcutaneous2 mg
Solutionintravenous; subcutaneous5 mg
Solutionintramuscular; intravenous; subcutaneous10 mg
Solutionintramuscular; intravenous; subcutaneous15 mg
Solutionintravenous1 mg
Solutionintramuscular; intravenous; subcutaneous2 mg
Solutionintravenous5 mg
Solutionintramuscular; intravenous; subcutaneous1 mg
Liquidintramuscular; intravenous; subcutaneous2 mg
Liquidintravenous; subcutaneous1 mg
Liquidintravenous; subcutaneous2 mg
Liquidintramuscular; intravenous; subcutaneous50 mg
Liquidintramuscular; intravenous; subcutaneous25 mg
Liquidintravenous25 mg
Liquidintravenous50 mg
Liquidintravenous; refer (see dosage form)1.1 mg
Solutionepidural0.5 mg
Solutionepidural1 mg
Tablet (extended-release)oral100 mg
Tablet (extended-release)oral15 mg
Tablet (extended-release)oral200 mg
Tablet (extended-release)oral30 mg
Tablet (extended-release)oral60 mg
Suppository (sustained-release)rectal30 mg
Suppository (sustained-release)rectal100 mg
Suppository (sustained-release)rectal200 mg
Suppository (sustained-release)rectal60 mg
Tablet (extended-release)oral5 mg
Capsule (sustained-release)oral120 mg
Capsule (sustained-release)oral150 mg
Capsule (sustained-release)oral200 mg
Capsule (sustained-release)oral30 mg
Capsule (sustained-release)oral60 mg
Capsule (sustained-release)oral90 mg
Suppositoryrectal10 mg
Tabletoral10 mg
Tabletoral20 mg
Tabletoral30 mg
Tabletoral5 mg
Liquidoral2 mg/5mL
Tinctureoral10 mg
Solutionoral1 g/100mL
Solutionoral10 mg/mL
Tinctureoral10 mg/mL
Syruporal20 mg
Dropsoral50 mg
Dropsoral20 mg
Suppositoryrectal20 mg
Suppositoryrectal30 mg
Suppositoryrectal5 mg
Syruporal10 mg
Syruporal1 mg
Syruporal5 mg
Tabletoral25 mg
Tabletoral50 mg
Capsule (sustained-release)oral20 mg
Capsule (sustained-release)oral40 mg
Prices
Unit descriptionCostUnit
Depodur 15 mg/1.5 ml vial618.18USD ml
Roxanol 20 mg/ml Solution 120ml Bottle95.98USD bottle
Morphine Sulfate 20 mg/5ml Solution 500ml Bottle65.05USD bottle
Apokyn 30 mg/3 ml cartridge52.48USD ml
Morphine Sulfate 10 mg/5ml Solution 500ml Bottle38.55USD bottle
Kadian er 200 mg capsule35.43USD capsule
Kadian er 100 mg capsule23.01USD capsule
Roxanol 20 mg/ml Solution 30ml Bottle22.99USD bottle
Morphine Sulfate 10 mg/5ml Solution 100ml Bottle21.99USD bottle
Oramorph sr 60 mg tablet21.76USD tablet
Ms contin 200 mg tablet21.5USD tablet
Kadian er 80 mg capsule18.66USD capsule
Roxanol 20 mg/ml Solution 240ml Bottle17.99USD bottle
Avinza 90 mg capsule17.56USD capsule
Oramorph sr 100 mg tablet17.16USD tablet
Kadian 100 mg 24 Hour Capsule16.93USD capsule
MS Contin 200 mg 12 Hour tablet16.32USD tablet
Kadian 100 mg capsule sr16.25USD capsule
Kadian er 60 mg capsule14.31USD capsule
AVINza 90 mg 24 Hour Capsule13.21USD capsule
Kadian 80 mg capsule sr12.96USD capsule
Avinza 120 mg capsule12.07USD capsule
Kadian er 50 mg capsule11.76USD capsule
Ms contin 100 mg tablet11.75USD tablet
Avinza 60 mg capsule11.58USD capsule
AVINza 120 mg 24 Hour Capsule11.33USD capsule
Avinza 75 mg capsule10.79USD capsule
Morphine sulfate powder10.61USD g
Avinza 45 mg capsule10.22USD capsule
Kadian 60 mg 24 Hour Capsule9.06USD capsule
Morphine Sulfate CR 200 mg 12 Hour tablet8.97USD tablet
MS Contin 100 mg 12 Hour tablet8.89USD tablet
Morphine sulf 30 mg suppository8.44USD suppository
AVINza 60 mg 24 Hour Capsule8.36USD capsule
Ms contin 60 mg tablet7.95USD tablet
Infumorph 10 mg/ml ampul p-f7.8USD ml
Kadian 50 mg 24 Hour Capsule7.71USD capsule
Kadian er 30 mg capsule7.13USD capsule
Oramorph sr 30 mg tablet6.83USD tablet
Morphine sulf 20 mg suppository6.71USD suppository
Kadian er 10 mg capsule6.35USD capsule
Morphine sulf 10 mg suppository6.25USD suppository
Avinza 30 mg capsule6.0USD capsule
MS Contin 60 mg 12 Hour tablet5.71USD tablet
Kadian er 20 mg capsule5.69USD capsule
Ms Contin 200 mg Sustained-Release Tablet5.62USD tablet
Kadian 30 mg 24 Hour Capsule4.8USD capsule
Kadian 20 mg 24 Hour Capsule4.76USD capsule
AVINza 30 mg 24 Hour Capsule4.47USD capsule
Morphine sulf 5 mg suppository4.45USD suppository
Morphine Sulfate CR 100 mg 12 Hour tablet4.33USD tablet
M-Eslon 200 mg Extended-Release Capsule4.3USD capsule
Oramorph sr 15 mg tablet4.12USD tablet
Ms contin cr 30 mg tablet4.09USD tablet
Kadian 10 mg capsule sr4.05USD capsule
Morphine Hp 50 50 mg/ml4.01USD ml
Kadian 10 mg 24 Hour Capsule4.0USD capsule
Ms contin 15 mg tablet3.58USD tablet
MS Contin 30 mg 12 Hour tablet3.26USD tablet
Novo-Morphine Sr 200 mg Sustained-Release Tablet3.09USD tablet
Pms-Morphine Sulfate Sr 200 mg Sustained-Release Tablet3.09USD tablet
Ms Contin 100 mg Sustained-Release Tablet3.02USD tablet
Morphine Sulfate CR 60 mg 12 Hour tablet3.0USD tablet
Morphine Hp 25 25 mg/ml2.9USD ml
Statex 30 mg Suppository2.55USD suppository
Kadian 100 mg Sustained-Release Capsule2.35USD capsule
Statex 20 mg Suppository2.32USD suppository
Morphine Lp Epidural 1 mg/ml2.24USD ml
M-Eslon 100 mg Extended-Release Capsule2.15USD capsule
MS Contin 15 mg 12 Hour tablet2.13USD tablet
Ms Contin 60 mg Sustained-Release Tablet1.98USD tablet
Statex 10 mg Suppository1.95USD suppository
Morph sulf 5 mg/0.25 ml vial1.83USD vial
Statex 5 mg Suppository1.75USD suppository
Novo-Morphine Sr 100 mg Sustained-Release Tablet1.66USD tablet
Pms-Morphine Sulfate Sr 100 mg Sustained-Release Tablet1.66USD tablet
Morphine Sulfate CR 30 mg 12 Hour tablet1.63USD tablet
Morphine 8 mg/ml ampule1.56USD ml
Kadian 50 mg Sustained-Release Capsule1.35USD capsule
Duramorph 0.5 mg/ml ampul1.31USD ml
Astramorph-pf 1 mg/ml ampul1.15USD ml
Ms Contin 30 mg Sustained-Release Tablet1.13USD tablet
Morphine Lp Epidural 0.5 mg/ml1.12USD ml
Morphine Sulfate 15 mg/ml1.03USD ml
Morphine Sulfate 10 mg/ml1.02USD ml
Novo-Morphine Sr 60 mg Sustained-Release Tablet1.01USD tablet
Pms-Morphine Sulfate Sr 60 mg Sustained-Release Tablet1.01USD tablet
Ratio-Morphine Sulfate Sr 60 mg Sustained-Release Tablet1.01USD tablet
M-Eslon 60 mg Extended-Release Capsule1.0USD capsule
Statex 50 mg/ml Drops0.99USD ml
Morphine Sulfate CR 15 mg 12 Hour tablet0.93USD tablet
Duramorph 1 mg/ml ampul0.91USD ml
M.O.S.-Sr 60 mg Sustained-Release Tablet0.89USD tablet
Morphine 50 mg/25 ml-d5w syr0.86USD ml
Morphine-ns 10 mg/ml syringe0.86USD ml
Morphine-ns 5 mg/ml syringe0.8USD ml
Ms Contin 15 mg Sustained-Release Tablet0.75USD tablet
Morphine 5 mg/ml vial0.74USD ml
Kadian 20 mg Sustained-Release Capsule0.73USD capsule
Astramorph-pf 0.5 mg/ml amp0.72USD ml
Morphine Sulfate 15 mg tablet0.65USD tablet
Morphine Sulfate 30 mg tablet0.65USD tablet
Morphine 1 mg/ml vial p-f0.6USD ml
Morphine-ns 1 mg/ml syringe0.58USD ml
Novo-Morphine Sr 30 mg Sustained-Release Tablet0.57USD tablet
Pms-Morphine Sulfate Sr 30 mg Sustained-Release Tablet0.57USD tablet
Ratio-Morphine Sulfate Sr 30 mg Sustained-Release Tablet0.57USD tablet
M-Eslon 30 mg Extended-Release Capsule0.56USD capsule
Morphine 0.5 mg/ml vial0.55USD ml
Morphine sulfate 50 mg/ml vial0.55USD ml
Morphine sulfate ir 30 mg tablet0.55USD tablet
Ratio-Morphine 20 mg/ml Syrup0.55USD syrup
Statex 20 mg/ml Drops0.52USD ml
M.O.S.-Sr 30 mg Sustained-Release Tablet0.51USD tablet
Morphine 1 mg/ml syringe0.48USD ml
Morphine 10 mg/ml vial0.48USD ml
Ms.Ir 30 mg Tablet0.48USD tablet
Morphine sulfate 25 mg/ml vial0.43USD ml
Morphine sulf 1 mg/ml vial0.4USD ml
M.O.S. Sulfate 50 mg Tablet0.39USD tablet
Statex 50 mg Tablet0.39USD tablet
Kadian 10 mg Sustained-Release Capsule0.38USD capsule
M-Eslon 15 mg Extended-Release Capsule0.38USD capsule
Ms.Ir 20 mg Tablet0.38USD tablet
Novo-Morphine Sr 15 mg Sustained-Release Tablet0.37USD tablet
Pms-Morphine Sulfate Sr 15 mg Sustained-Release Tablet0.37USD tablet
Ratio-Morphine Sulfate Sr 15 mg Sustained-Release Tablet0.37USD tablet
M-Eslon 10 mg Extended-Release Capsule0.33USD capsule
Morphine sulfate ir 15 mg tablet0.32USD tablet
Morphine 15 mg/ml vial0.3USD ml
Morphine-ns 25 mg/25 ml syr0.26USD ml
M.O.S. Sulfate 25 mg Tablet0.25USD tablet
Statex 25 mg Tablet0.25USD tablet
Ms.Ir 10 mg Tablet0.21USD tablet
Ratio-Morphine 10 mg/ml Syrup0.19USD syrup
M.O.S. Sulfate 10 mg Tablet0.19USD tablet
Statex 10 mg Tablet0.19USD tablet
Morphine-ns 5 mg/ml0.16USD ml
Morphine-ns 55 mg/55 ml syr0.14USD ml
Ms.Ir 5 mg Tablet0.14USD tablet
M.O.S. Sulfate 5 mg Tablet0.12USD tablet
Statex 5 mg Tablet0.12USD tablet
Morphine 1 mg/ml-d5w 100 ml0.1USD ml
Morphine-ns 150 mg/150 ml0.1USD ml
Statex 5 mg/ml Syrup0.08USD ml
Morphine 1 mg/ml-d5w 250 ml0.06USD ml
Ratio-Morphine 5 mg/ml Syrup0.05USD syrup
Ratio-Morphine 1 mg/ml Syrup0.02USD syrup
Statex 1 mg/ml Syrup0.02USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2065210 No2000-08-292012-04-06Canada
CA2128591 No1999-03-232014-07-21Canada
US5378474 No1993-03-232010-03-23Us
US5807572 No1995-09-152015-09-15Us
US5891467 No1997-01-312017-01-31Us
US5931809 No1995-07-142015-07-14Us
US5962016 No1997-01-312017-01-31Us
US5997899 No1996-09-012016-09-01Us
US6066339 No1997-11-252017-11-25Us
US6171613 No1996-10-012016-10-01Us
US6193998 No1996-09-012016-09-01Us
US6241999 No1996-09-012016-09-01Us
US7682633 No2007-06-192027-06-19Us
US7682634 No2007-06-192027-06-19Us
US7815934 No2007-12-122027-12-12Us
US7955619 No2008-08-122028-08-12Us
US8158156 No2007-06-192027-06-19Us
US8623418 No2009-11-072029-11-07Us
US8685443 No2005-07-032025-07-03Us
US8685444 No2005-07-032025-07-03Us
US8846104 No2007-06-192027-06-19Us
US8877247 No2007-06-192027-06-19Us
US9072781 No2014-03-122034-03-12Us
US9192608 No2014-03-122034-03-12Us
US9248229 No2014-03-122034-03-12Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point255 °CPhysProp
water solubility149 mg/L (at 20 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP0.89AVDEEF,A ET AL. (1996)
logS-3.28ADME Research, USCD
pKa8.21 (at 25 °C)LIDE,DR (1995)
Predicted Properties
PropertyValueSource
Water Solubility10.2 mg/mLALOGPS
logP0.99ALOGPS
logP0.9ChemAxon
logS-1.4ALOGPS
pKa (Strongest Acidic)10.26ChemAxon
pKa (Strongest Basic)9.12ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area52.93 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity80.12 m3·mol-1ChemAxon
Polarizability29.95 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (9.42 KB)
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Nagaraj R. Ayyangar, Anil R. Choudhary, Uttam R. Kalkote, Vasant K. Sharma, “Process for the preparation of codeine from morphine.” U.S. Patent US4764615, issued May, 1912.

US4764615
General References
  1. Kilpatrick GJ, Smith TW: Morphine-6-glucuronide: actions and mechanisms. Med Res Rev. 2005 Sep;25(5):521-44. [PubMed:15952175 ]
  2. Loguinov AV, Anderson LM, Crosby GJ, Yukhananov RY: Gene expression following acute morphine administration. Physiol Genomics. 2001 Aug 28;6(3):169-81. [PubMed:11526201 ]
External Links
ATC CodesN02AG01N02AA51A07DA52N02AA01
AHFS Codes
  • 28:08.08
  • 84:24.12
PDB EntriesNot Available
FDA labelDownload (1.2 MB)
MSDSDownload (51.7 KB)
Interactions
Drug Interactions
Drug
3,4-Methylenedioxyamphetamine3,4-Methylenedioxyamphetamine may increase the analgesic activities of Morphine.
3,4-Methylenedioxymethamphetamine3,4-Methylenedioxymethamphetamine may increase the analgesic activities of Morphine.
7-NitroindazoleThe risk or severity of adverse effects can be increased when Morphine is combined with 7-Nitroindazole.
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINEThe risk or severity of adverse effects can be increased when 7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE is combined with Morphine.
AbirateroneThe serum concentration of Morphine can be increased when it is combined with Abiraterone.
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Morphine.
AcepromazineAcepromazine may increase the hypotensive activities of Morphine.
AcepromazineThe risk or severity of adverse effects can be increased when Morphine is combined with Acepromazine.
AceprometazineThe risk or severity of adverse effects can be increased when Morphine is combined with Aceprometazine.
AcetaminophenThe serum concentration of Morphine can be increased when it is combined with Acetaminophen.
AcetazolamideThe risk or severity of adverse effects can be increased when Morphine is combined with Acetazolamide.
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Morphine.
AclidiniumThe risk or severity of adverse effects can be increased when Aclidinium is combined with Morphine.
adipiplonThe risk or severity of adverse effects can be increased when Morphine is combined with adipiplon.
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Morphine.
AgomelatineThe risk or severity of adverse effects can be increased when Morphine is combined with Agomelatine.
AlbendazoleThe serum concentration of Morphine can be increased when it is combined with Albendazole.
AldosteroneThe serum concentration of Morphine can be decreased when it is combined with Aldosterone.
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Morphine.
AlectinibThe serum concentration of Morphine can be increased when it is combined with Alectinib.
AlfaxaloneThe risk or severity of adverse effects can be increased when Morphine is combined with Alfaxalone.
AlfentanilThe serum concentration of Morphine can be increased when it is combined with Alfentanil.
AlfentanilThe risk or severity of adverse effects can be increased when Morphine is combined with Alfentanil.
AlimemazineAlimemazine may increase the hypotensive activities of Morphine.
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Morphine.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Morphine is combined with Alphacetylmethadol.
AlprazolamThe risk or severity of adverse effects can be increased when Morphine is combined with Alprazolam.
AlvimopanThe risk or severity of adverse effects can be increased when Morphine is combined with Alvimopan.
AmantadineThe serum concentration of Morphine can be increased when it is combined with Amantadine.
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Morphine.
AmilorideThe risk or severity of adverse effects can be increased when Morphine is combined with Amiloride.
Aminohippuric acidThe serum concentration of Morphine can be increased when it is combined with Aminohippuric acid.
AmiodaroneThe serum concentration of Morphine can be decreased when it is combined with Amiodarone.
AmisulprideThe risk or severity of adverse effects can be increased when Morphine is combined with Amisulpride.
AmitriptylineThe serum concentration of Morphine can be increased when it is combined with Amitriptyline.
AmlodipineThe serum concentration of Morphine can be increased when it is combined with Amlodipine.
Ammonium chlorideAmmonium chloride may increase the excretion rate of Morphine which could result in a higher serum level.
AmobarbitalThe risk or severity of adverse effects can be increased when Morphine is combined with Amobarbital.
AmoxapineMorphine may increase the serotonergic activities of Amoxapine.
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Morphine.
AmperozideThe risk or severity of adverse effects can be increased when Morphine is combined with Amperozide.
AmphetamineAmphetamine may increase the analgesic activities of Morphine.
AmprenavirThe serum concentration of Morphine can be decreased when it is combined with Amprenavir.
AmsacrineThe serum concentration of Morphine can be increased when it is combined with Amsacrine.
Anisotropine MethylbromideThe risk or severity of adverse effects can be increased when Anisotropine Methylbromide is combined with Morphine.
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Morphine.
AprepitantThe serum concentration of Morphine can be increased when it is combined with Aprepitant.
AripiprazoleThe risk or severity of adverse effects can be increased when Morphine is combined with Aripiprazole.
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Morphine.
ArtemetherThe metabolism of Morphine can be decreased when combined with Artemether.
ArticaineThe risk or severity of adverse effects can be increased when Morphine is combined with Articaine.
AsenapineThe risk or severity of adverse effects can be increased when Morphine is combined with Asenapine.
AstemizoleThe serum concentration of Morphine can be increased when it is combined with Astemizole.
AtazanavirThe serum concentration of Atazanavir can be increased when it is combined with Morphine.
AtenololThe serum concentration of Morphine can be increased when it is combined with Atenolol.
AtomoxetineThe metabolism of Morphine can be decreased when combined with Atomoxetine.
AtorvastatinThe serum concentration of Morphine can be increased when it is combined with Atorvastatin.
Atracurium besylateThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Morphine.
AtropineThe risk or severity of adverse effects can be increased when Atropine is combined with Morphine.
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Morphine.
AzaperoneThe risk or severity of adverse effects can be increased when Morphine is combined with Azaperone.
AzelastineMorphine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe serum concentration of Morphine can be increased when it is combined with Azelastine.
AzithromycinThe serum concentration of Morphine can be increased when it is combined with Azithromycin.
AzosemideThe risk or severity of adverse effects can be increased when Morphine is combined with Azosemide.
BaclofenThe risk or severity of adverse effects can be increased when Morphine is combined with Baclofen.
BarbitalThe risk or severity of adverse effects can be increased when Morphine is combined with Barbital.
BenactyzineThe risk or severity of adverse effects can be increased when Benactyzine is combined with Morphine.
BendroflumethiazideThe risk or severity of adverse effects can be increased when Morphine is combined with Bendroflumethiazide.
BenmoxinThe risk or severity of adverse effects can be increased when Benmoxin is combined with Morphine.
BenzatropineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Morphine.
BenzocaineThe serum concentration of Morphine can be increased when it is combined with Benzocaine.
BenzocaineThe risk or severity of adverse effects can be increased when Morphine is combined with Benzocaine.
BenzphetamineBenzphetamine may increase the analgesic activities of Morphine.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Morphine is combined with Benzyl alcohol.
BepridilThe serum concentration of Morphine can be increased when it is combined with Bepridil.
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Morphine.
BetaxololThe metabolism of Morphine can be decreased when combined with Betaxolol.
BexaroteneThe serum concentration of Morphine can be decreased when it is combined with Bexarotene.
BiperidenThe risk or severity of adverse effects can be increased when Biperiden is combined with Morphine.
BoceprevirThe metabolism of Morphine can be decreased when combined with Boceprevir.
BoceprevirThe serum concentration of Boceprevir can be increased when it is combined with Morphine.
BortezomibThe metabolism of Morphine can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Morphine can be decreased when it is combined with Bosentan.
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Morphine.
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Morphine.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Morphine is combined with Brexpiprazole.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Morphine.
BrimonidineThe risk or severity of adverse effects can be increased when Morphine is combined with Brimonidine.
BromazepamThe risk or severity of adverse effects can be increased when Morphine is combined with Bromazepam.
BromocriptineThe serum concentration of Morphine can be increased when it is combined with Bromocriptine.
BrompheniramineThe risk or severity of adverse effects can be increased when Morphine is combined with Brompheniramine.
BrotizolamThe risk or severity of adverse effects can be increased when Morphine is combined with Brotizolam.
BumetanideThe risk or severity of adverse effects can be increased when Morphine is combined with Bumetanide.
BupivacaineThe risk or severity of adverse effects can be increased when Morphine is combined with Bupivacaine.
BuprenorphineBuprenorphine may decrease the analgesic activities of Morphine.
BuprenorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Buprenorphine.
BupropionThe metabolism of Morphine can be decreased when combined with Bupropion.
BuspironeThe serum concentration of Morphine can be increased when it is combined with Buspirone.
BuspironeThe risk or severity of adverse effects can be increased when Morphine is combined with Buspirone.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Morphine.
ButacaineThe risk or severity of adverse effects can be increased when Morphine is combined with Butacaine.
ButalbitalThe risk or severity of adverse effects can be increased when Morphine is combined with Butalbital.
ButambenThe risk or severity of adverse effects can be increased when Morphine is combined with Butamben.
ButethalThe risk or severity of adverse effects can be increased when Morphine is combined with Butethal.
ButorphanolButorphanol may decrease the analgesic activities of Morphine.
ButorphanolThe risk or severity of adverse effects can be increased when Morphine is combined with Butorphanol.
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Morphine.
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Morphine.
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Morphine.
CanagliflozinThe serum concentration of Canagliflozin can be increased when it is combined with Morphine.
CandesartanThe serum concentration of Morphine can be increased when it is combined with Candesartan.
Canrenoic acidThe risk or severity of adverse effects can be increased when Morphine is combined with Canrenoic acid.
CaptoprilThe serum concentration of Morphine can be increased when it is combined with Captopril.
CarbamazepineThe serum concentration of Morphine can be decreased when it is combined with Carbamazepine.
CarbamazepineThe serum concentration of Carbamazepine can be increased when it is combined with Morphine.
CarbinoxamineThe risk or severity of adverse effects can be increased when Morphine is combined with Carbinoxamine.
CarfentanilThe risk or severity of adverse effects can be increased when Morphine is combined with Carfentanil.
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Morphine.
CarisoprodolThe risk or severity of adverse effects can be increased when Morphine is combined with Carisoprodol.
CaroxazoneThe risk or severity of adverse effects can be increased when Caroxazone is combined with Morphine.
CarvedilolThe serum concentration of Morphine can be increased when it is combined with Carvedilol.
CaspofunginThe serum concentration of Morphine can be increased when it is combined with Caspofungin.
CelecoxibThe metabolism of Morphine can be decreased when combined with Celecoxib.
CeritinibThe serum concentration of Morphine can be increased when it is combined with Ceritinib.
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Morphine.
CetirizineThe risk or severity of adverse effects can be increased when Morphine is combined with Cetirizine.
Chloral hydrateThe risk or severity of adverse effects can be increased when Morphine is combined with Chloral hydrate.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Morphine is combined with Chlordiazepoxide.
ChlormezanoneThe risk or severity of adverse effects can be increased when Morphine is combined with Chlormezanone.
ChloroprocaineThe risk or severity of adverse effects can be increased when Morphine is combined with Chloroprocaine.
ChloroquineThe serum concentration of Morphine can be increased when it is combined with Chloroquine.
ChlorothiazideThe risk or severity of adverse effects can be increased when Morphine is combined with Chlorothiazide.
ChlorphenamineThe risk or severity of adverse effects can be increased when Morphine is combined with Chlorphenamine.
ChlorphenoxamineThe risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Morphine.
ChlorphentermineChlorphentermine may increase the analgesic activities of Morphine.
ChlorpromazineChlorpromazine may increase the hypotensive activities of Morphine.
ChlorpromazineThe serum concentration of Chlorpromazine can be increased when it is combined with Morphine.
ChlorpropamideThe serum concentration of Morphine can be increased when it is combined with Chlorpropamide.
ChlorprothixeneThe serum concentration of Morphine can be increased when it is combined with Chlorprothixene.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Morphine is combined with Chlorprothixene.
ChlorthalidoneThe risk or severity of adverse effects can be increased when Morphine is combined with Chlorthalidone.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Morphine is combined with Chlorzoxazone.
CholecalciferolThe metabolism of Morphine can be decreased when combined with Cholecalciferol.
CholesterolThe serum concentration of Morphine can be increased when it is combined with Cholesterol.
Cholic AcidThe serum concentration of Morphine can be decreased when it is combined with Cholic Acid.
CilazaprilThe serum concentration of Morphine can be increased when it is combined with Cilazapril.
CimetidineThe serum concentration of Morphine can be decreased when it is combined with Cimetidine.
CimetidineThe serum concentration of Cimetidine can be increased when it is combined with Morphine.
CinacalcetThe metabolism of Morphine can be decreased when combined with Cinacalcet.
CinchocaineThe risk or severity of adverse effects can be increased when Morphine is combined with Cinchocaine.
CiprofloxacinThe serum concentration of Morphine can be increased when it is combined with Ciprofloxacin.
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Morphine.
CitalopramMorphine may increase the serotonergic activities of Citalopram.
CitalopramThe serum concentration of Morphine can be increased when it is combined with Citalopram.
ClarithromycinThe serum concentration of Morphine can be increased when it is combined with Clarithromycin.
ClemastineThe metabolism of Morphine can be decreased when combined with Clemastine.
ClemastineThe risk or severity of adverse effects can be increased when Morphine is combined with Clemastine.
ClidiniumThe risk or severity of adverse effects can be increased when Morphine is combined with Clidinium.
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Morphine.
ClobazamThe metabolism of Morphine can be decreased when combined with Clobazam.
ClofazimineThe serum concentration of Morphine can be increased when it is combined with Clofazimine.
clomethiazoleThe risk or severity of adverse effects can be increased when Morphine is combined with clomethiazole.
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Morphine.
ClomipramineMorphine may increase the serotonergic activities of Clomipramine.
ClomipramineThe serum concentration of Morphine can be increased when it is combined with Clomipramine.
ClonazepamThe risk or severity of adverse effects can be increased when Morphine is combined with Clonazepam.
ClonidineThe serum concentration of Clonidine can be increased when it is combined with Morphine.
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Morphine.
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Morphine.
ClopidogrelThe metabolism of Morphine can be decreased when combined with Clopidogrel.
ClorazepateThe risk or severity of adverse effects can be increased when Morphine is combined with Clorazepate.
ClotrimazoleThe metabolism of Morphine can be decreased when combined with Clotrimazole.
ClozapineThe serum concentration of Clozapine can be increased when it is combined with Morphine.
ClozapineThe metabolism of Morphine can be decreased when combined with Clozapine.
CobicistatThe serum concentration of Morphine can be increased when it is combined with Cobicistat.
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Morphine.
CocaineThe risk or severity of adverse effects can be increased when Morphine is combined with Cocaine.
CodeineThe risk or severity of adverse effects can be increased when Morphine is combined with Codeine.
ColchicineThe serum concentration of Morphine can be increased when it is combined with Colchicine.
ColforsinThe serum concentration of Morphine can be increased when it is combined with Colforsin.
ConivaptanThe serum concentration of Morphine can be increased when it is combined with Conivaptan.
ConivaptanThe risk or severity of adverse effects can be increased when Morphine is combined with Conivaptan.
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Morphine.
CrizotinibThe metabolism of Morphine can be decreased when combined with Crizotinib.
CrizotinibThe serum concentration of Crizotinib can be increased when it is combined with Morphine.
CyclizineThe risk or severity of adverse effects can be increased when Morphine is combined with Cyclizine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Morphine is combined with Cyclobenzaprine.
CyclopentolateThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Morphine.
CyclophosphamideThe serum concentration of Morphine can be increased when it is combined with Cyclophosphamide.
CyclosporineThe metabolism of Morphine can be decreased when combined with Cyclosporine.
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Morphine.
CyclothiazideThe risk or severity of adverse effects can be increased when Morphine is combined with Cyclothiazide.
CyproheptadineThe risk or severity of adverse effects can be increased when Morphine is combined with Cyproheptadine.
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be increased when it is combined with Morphine.
DabrafenibThe serum concentration of Morphine can be decreased when it is combined with Dabrafenib.
DabrafenibThe serum concentration of Dabrafenib can be increased when it is combined with Morphine.
DaclatasvirThe serum concentration of Morphine can be increased when it is combined with Daclatasvir.
DactinomycinThe serum concentration of Morphine can be increased when it is combined with Dactinomycin.
DantroleneThe risk or severity of adverse effects can be increased when Morphine is combined with Dantrolene.
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Morphine.
DapiprazoleThe risk or severity of adverse effects can be increased when Morphine is combined with Dapiprazole.
DapoxetineMorphine may increase the serotonergic activities of Dapoxetine.
DarifenacinThe risk or severity of adverse effects can be increased when Darifenacin is combined with Morphine.
DarunavirThe serum concentration of Morphine can be increased when it is combined with Darunavir.
DasatinibThe serum concentration of Morphine can be increased when it is combined with Dasatinib.
DaunorubicinThe serum concentration of Morphine can be decreased when it is combined with Daunorubicin.
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Morphine.
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Morphine.
DeferasiroxThe serum concentration of Morphine can be decreased when it is combined with Deferasirox.
DelavirdineThe metabolism of Morphine can be decreased when combined with Delavirdine.
deramciclaneThe risk or severity of adverse effects can be increased when Morphine is combined with deramciclane.
DesfluraneThe risk or severity of adverse effects can be increased when Morphine is combined with Desflurane.
DesipramineThe serum concentration of Morphine can be increased when it is combined with Desipramine.
DesipramineThe risk or severity of adverse effects can be increased when Morphine is combined with Desipramine.
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Morphine.
DesmopressinThe risk or severity of adverse effects can be increased when Morphine is combined with Desmopressin.
DetomidineThe risk or severity of adverse effects can be increased when Morphine is combined with Detomidine.
DexamethasoneThe serum concentration of Morphine can be decreased when it is combined with Dexamethasone.
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Morphine.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Morphine is combined with Dexbrompheniramine.
DexetimideThe risk or severity of adverse effects can be increased when Dexetimide is combined with Morphine.
DexmedetomidineThe risk or severity of adverse effects can be increased when Morphine is combined with Dexmedetomidine.
DextroamphetamineDextroamphetamine may increase the analgesic activities of Morphine.
DextromethorphanThe serum concentration of Morphine can be increased when it is combined with Dextromethorphan.
DextromoramideThe risk or severity of adverse effects can be increased when Morphine is combined with Dextromoramide.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Morphine is combined with Dextropropoxyphene.
DezocineThe risk or severity of adverse effects can be increased when Morphine is combined with Dezocine.
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Morphine.
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Morphine.
DiclofenacThe serum concentration of Morphine can be increased when it is combined with Diclofenac.
DicyclomineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Morphine.
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Morphine.
DifenoxinThe risk or severity of adverse effects can be increased when Morphine is combined with Difenoxin.
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Morphine.
DigoxinThe serum concentration of Morphine can be decreased when it is combined with Digoxin.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Morphine.
DihydrocodeineThe risk or severity of adverse effects can be increased when Morphine is combined with Dihydrocodeine.
DihydroergotamineThe metabolism of Morphine can be decreased when combined with Dihydroergotamine.
DihydroetorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Dihydroetorphine.
DihydromorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Dihydromorphine.
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Morphine.
DiltiazemThe metabolism of Morphine can be decreased when combined with Diltiazem.
DiltiazemThe serum concentration of Diltiazem can be increased when it is combined with Morphine.
DimenhydrinateThe risk or severity of adverse effects can be increased when Morphine is combined with Dimenhydrinate.
DiphenhydramineThe metabolism of Morphine can be decreased when combined with Diphenhydramine.
DiphenhydramineThe risk or severity of adverse effects can be increased when Morphine is combined with Diphenhydramine.
DiphenoxylateThe risk or severity of adverse effects can be increased when Morphine is combined with Diphenoxylate.
DipyridamoleThe serum concentration of Morphine can be increased when it is combined with Dipyridamole.
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Morphine.
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Morphine.
DoramectinThe risk or severity of adverse effects can be increased when Morphine is combined with Doramectin.
DoxazosinThe serum concentration of Morphine can be increased when it is combined with Doxazosin.
DoxepinThe serum concentration of Morphine can be increased when it is combined with Doxepin.
DoxepinThe risk or severity of adverse effects can be increased when Morphine is combined with Doxepin.
DoxorubicinThe serum concentration of Morphine can be decreased when it is combined with Doxorubicin.
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Morphine.
DoxycyclineThe metabolism of Morphine can be decreased when combined with Doxycycline.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Morphine.
DoxylamineThe risk or severity of adverse effects can be increased when Morphine is combined with Doxylamine.
DPDPEThe risk or severity of adverse effects can be increased when Morphine is combined with DPDPE.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Morphine.
DronedaroneThe metabolism of Morphine can be decreased when combined with Dronedarone.
DroperidolThe risk or severity of adverse effects can be increased when Morphine is combined with Droperidol.
DrospirenoneThe risk or severity of adverse effects can be increased when Morphine is combined with Drospirenone.
DrotebanolThe risk or severity of adverse effects can be increased when Morphine is combined with Drotebanol.
DuloxetineThe metabolism of Morphine can be decreased when combined with Duloxetine.
DyclonineThe risk or severity of adverse effects can be increased when Morphine is combined with Dyclonine.
EcgonineThe risk or severity of adverse effects can be increased when Morphine is combined with Ecgonine.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Morphine is combined with ECGONINE METHYL ESTER.
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Morphine.
EfavirenzThe serum concentration of Morphine can be decreased when it is combined with Efavirenz.
EfavirenzThe risk or severity of adverse effects can be increased when Morphine is combined with Efavirenz.
EfonidipineThe risk or severity of adverse effects can be increased when Morphine is combined with Efonidipine.
ElbasvirThe serum concentration of Morphine can be increased when it is combined with Elbasvir.
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Morphine.
EliglustatThe metabolism of Morphine can be decreased when combined with Eliglustat.
EluxadolineMorphine may increase the constipating activities of Eluxadoline.
EnalaprilThe serum concentration of Morphine can be increased when it is combined with Enalapril.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Morphine.
EntacaponeThe risk or severity of adverse effects can be increased when Morphine is combined with Entacapone.
EnzalutamideThe serum concentration of Morphine can be increased when it is combined with Enzalutamide.
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Morphine.
EplerenoneThe risk or severity of adverse effects can be increased when Morphine is combined with Eplerenone.
ErgonovineThe serum concentration of Morphine can be increased when it is combined with Ergonovine.
ErgotamineThe serum concentration of Morphine can be increased when it is combined with Ergotamine.
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Morphine.
ErythromycinThe metabolism of Morphine can be decreased when combined with Erythromycin.
ErythromycinThe serum concentration of Erythromycin can be increased when it is combined with Morphine.
EscitalopramMorphine may increase the serotonergic activities of Escitalopram.
Eslicarbazepine acetateThe serum concentration of Morphine can be decreased when it is combined with Eslicarbazepine acetate.
EstazolamThe risk or severity of adverse effects can be increased when Morphine is combined with Estazolam.
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Morphine.
EstramustineThe serum concentration of Morphine can be increased when it is combined with Estramustine.
EstriolThe serum concentration of Morphine can be decreased when it is combined with Estriol.
EstriolThe serum concentration of Estriol can be increased when it is combined with Morphine.
EstroneThe serum concentration of Morphine can be decreased when it is combined with Estrone.
EstroneThe serum concentration of Estrone can be increased when it is combined with Morphine.
EszopicloneThe risk or severity of adverse effects can be increased when Morphine is combined with Eszopiclone.
Etacrynic acidThe risk or severity of adverse effects can be increased when Morphine is combined with Etacrynic acid.
EthanolMorphine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Morphine.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Morphine.
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Morphine.
EthopropazineThe risk or severity of adverse effects can be increased when Ethopropazine is combined with Morphine.
EthosuximideThe risk or severity of adverse effects can be increased when Morphine is combined with Ethosuximide.
EthotoinThe risk or severity of adverse effects can be increased when Morphine is combined with Ethotoin.
EthoxzolamideThe risk or severity of adverse effects can be increased when Morphine is combined with Ethoxzolamide.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Morphine is combined with Ethyl carbamate.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Morphine is combined with Ethyl loflazepate.
EthylmorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Ethylmorphine.
EtidocaineThe risk or severity of adverse effects can be increased when Morphine is combined with Etidocaine.
EtifoxineThe risk or severity of adverse effects can be increased when Morphine is combined with Etifoxine.
EtizolamThe risk or severity of adverse effects can be increased when Morphine is combined with Etizolam.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Morphine.
EtoperidoneMorphine may increase the serotonergic activities of Etoperidone.
EtoposideThe serum concentration of Morphine can be increased when it is combined with Etoposide.
EtorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Etorphine.
EtravirineThe serum concentration of Morphine can be decreased when it is combined with Etravirine.
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Morphine.
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Morphine.
EzogabineThe risk or severity of adverse effects can be increased when Morphine is combined with Ezogabine.
FelbamateThe risk or severity of adverse effects can be increased when Morphine is combined with Felbamate.
FelodipineThe serum concentration of Morphine can be increased when it is combined with Felodipine.
FencamfamineThe risk or severity of adverse effects can be increased when Morphine is combined with Fencamfamine.
FenfluramineMorphine may increase the serotonergic activities of Fenfluramine.
FentanylThe serum concentration of Morphine can be increased when it is combined with Fentanyl.
FentanylThe risk or severity of adverse effects can be increased when Morphine is combined with Fentanyl.
FesoterodineThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Morphine.
FesoterodineThe serum concentration of Fesoterodine can be increased when it is combined with Morphine.
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Morphine.
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Morphine.
FlibanserinThe risk or severity of adverse effects can be increased when Morphine is combined with Flibanserin.
FluconazoleThe metabolism of Morphine can be decreased when combined with Fluconazole.
FludiazepamThe risk or severity of adverse effects can be increased when Morphine is combined with Fludiazepam.
FlunarizineThe risk or severity of adverse effects can be increased when Morphine is combined with Flunarizine.
FlunitrazepamThe risk or severity of adverse effects can be increased when Morphine is combined with Flunitrazepam.
FluoxetineMorphine may increase the serotonergic activities of Fluoxetine.
FluoxetineThe serum concentration of Morphine can be increased when it is combined with Fluoxetine.
FlupentixolThe serum concentration of Morphine can be increased when it is combined with Flupentixol.
FlupentixolThe risk or severity of adverse effects can be increased when Morphine is combined with Flupentixol.
FluphenazineFluphenazine may increase the hypotensive activities of Morphine.
FluphenazineThe risk or severity of adverse effects can be increased when Morphine is combined with Fluphenazine.
FlurazepamThe serum concentration of Morphine can be increased when it is combined with Flurazepam.
FlurazepamThe risk or severity of adverse effects can be increased when Morphine is combined with Flurazepam.
FluspirileneThe risk or severity of adverse effects can be increased when Morphine is combined with Fluspirilene.
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Morphine.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Morphine is combined with Fluticasone Propionate.
FluvoxamineMorphine may increase the serotonergic activities of Fluvoxamine.
FluvoxamineThe metabolism of Morphine can be decreased when combined with Fluvoxamine.
FosamprenavirThe metabolism of Morphine can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Morphine can be increased when it is combined with Fosaprepitant.
FosphenytoinThe risk or severity of adverse effects can be increased when Morphine is combined with Fosphenytoin.
FospropofolThe risk or severity of adverse effects can be increased when Morphine is combined with Fospropofol.
FurazolidoneThe risk or severity of adverse effects can be increased when Furazolidone is combined with Morphine.
FurosemideThe risk or severity of adverse effects can be increased when Morphine is combined with Furosemide.
Fusidic AcidThe serum concentration of Morphine can be increased when it is combined with Fusidic Acid.
GabapentinThe risk or severity of adverse effects can be increased when Morphine is combined with Gabapentin.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Morphine is combined with gabapentin enacarbil.
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Gallamine Triethiodide is combined with Morphine.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Morphine is combined with Gamma Hydroxybutyric Acid.
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Morphine.
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Morphine.
GemfibrozilThe metabolism of Morphine can be decreased when combined with Gemfibrozil.
GenisteinThe serum concentration of Morphine can be increased when it is combined with Genistein.
GlutethimideThe risk or severity of adverse effects can be increased when Morphine is combined with Glutethimide.
GlyburideThe serum concentration of Morphine can be increased when it is combined with Glyburide.
GlycerolThe serum concentration of Morphine can be increased when it is combined with Glycerol.
GlycopyrroniumThe risk or severity of adverse effects can be increased when Glycopyrronium is combined with Morphine.
Gramicidin DThe serum concentration of Morphine can be increased when it is combined with Gramicidin D.
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Morphine.
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Morphine.
GuanfacineThe risk or severity of adverse effects can be increased when Morphine is combined with Guanfacine.
HalazepamThe risk or severity of adverse effects can be increased when Morphine is combined with Halazepam.
HaloperidolThe serum concentration of Morphine can be increased when it is combined with Haloperidol.
HalothaneThe risk or severity of adverse effects can be increased when Morphine is combined with Halothane.
HeroinThe risk or severity of adverse effects can be increased when Morphine is combined with Heroin.
HexamethoniumThe risk or severity of adverse effects can be increased when Hexamethonium is combined with Morphine.
HexobarbitalThe risk or severity of adverse effects can be increased when Morphine is combined with Hexobarbital.
HomatropineThe risk or severity of adverse effects can be increased when Homatropine is combined with Morphine.
HydracarbazineThe risk or severity of adverse effects can be increased when Hydracarbazine is combined with Morphine.
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Morphine is combined with Hydrochlorothiazide.
HydrocodoneThe risk or severity of adverse effects can be increased when Morphine is combined with Hydrocodone.
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Morphine.
HydroflumethiazideThe risk or severity of adverse effects can be increased when Morphine is combined with Hydroflumethiazide.
HydromorphoneThe risk or severity of adverse effects can be increased when Morphine is combined with Hydromorphone.
Hydroxyamphetamine hydrobromideHydroxyamphetamine hydrobromide may increase the analgesic activities of Morphine.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Morphine.
HydroxyzineThe risk or severity of adverse effects can be increased when Morphine is combined with Hydroxyzine.
HyoscyamineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Morphine.
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Morphine.
IdelalisibThe serum concentration of Morphine can be increased when it is combined with Idelalisib.
IloperidoneThe risk or severity of adverse effects can be increased when Morphine is combined with Iloperidone.
ImatinibThe metabolism of Morphine can be decreased when combined with Imatinib.
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Morphine.
ImipramineThe serum concentration of Morphine can be increased when it is combined with Imipramine.
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Morphine.
IndalpineMorphine may increase the serotonergic activities of Indalpine.
IndapamideThe risk or severity of adverse effects can be increased when Morphine is combined with Indapamide.
IndinavirThe serum concentration of Morphine can be decreased when it is combined with Indinavir.
IndinavirThe serum concentration of Indinavir can be increased when it is combined with Morphine.
IndomethacinThe serum concentration of Morphine can be increased when it is combined with Indomethacin.
Ipratropium bromideThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Morphine.
IproclozideThe risk or severity of adverse effects can be increased when Iproclozide is combined with Morphine.
IproniazidThe risk or severity of adverse effects can be increased when Iproniazid is combined with Morphine.
IrbesartanThe metabolism of Morphine can be decreased when combined with Irbesartan.
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Morphine.
IsavuconazoniumThe metabolism of Morphine can be decreased when combined with Isavuconazonium.
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Morphine.
IsofluraneThe risk or severity of adverse effects can be increased when Morphine is combined with Isoflurane.
IsoniazidThe metabolism of Morphine can be decreased when combined with Isoniazid.
IsosorbideThe risk or severity of adverse effects can be increased when Morphine is combined with Isosorbide.
IsradipineThe metabolism of Morphine can be decreased when combined with Isradipine.
ItraconazoleThe serum concentration of Morphine can be increased when it is combined with Itraconazole.
IvacaftorThe serum concentration of Morphine can be increased when it is combined with Ivacaftor.
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Morphine.
KetamineThe serum concentration of Morphine can be increased when it is combined with Ketamine.
KetamineThe risk or severity of adverse effects can be increased when Morphine is combined with Ketamine.
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Morphine.
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Morphine.
KetobemidoneThe risk or severity of adverse effects can be increased when Morphine is combined with Ketobemidone.
KetoconazoleThe serum concentration of Morphine can be increased when it is combined with Ketoconazole.
KW-3902The risk or severity of adverse effects can be increased when Morphine is combined with KW-3902.
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Morphine.
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Morphine.
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Morphine.
LansoprazoleThe serum concentration of Morphine can be increased when it is combined with Lansoprazole.
LapatinibThe serum concentration of Morphine can be increased when it is combined with Lapatinib.
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Morphine.
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Morphine.
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Morphine.
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Morphine.
LevetiracetamThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Morphine.
LevobupivacaineThe risk or severity of adverse effects can be increased when Morphine is combined with Levobupivacaine.
LevocabastineThe risk or severity of adverse effects can be increased when Morphine is combined with Levocabastine.
LevocetirizineThe risk or severity of adverse effects can be increased when Morphine is combined with Levocetirizine.
LevodopaThe risk or severity of adverse effects can be increased when Morphine is combined with Levodopa.
LevofloxacinThe serum concentration of Levofloxacin can be increased when it is combined with Morphine.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Morphine is combined with Levomethadyl Acetate.
LevomilnacipranMorphine may increase the serotonergic activities of Levomilnacipran.
LevorphanolThe risk or severity of adverse effects can be increased when Morphine is combined with Levorphanol.
LevothyroxineThe serum concentration of Morphine can be decreased when it is combined with Levothyroxine.
LidocaineThe serum concentration of Morphine can be increased when it is combined with Lidocaine.
LidocaineThe risk or severity of adverse effects can be increased when Morphine is combined with Lidocaine.
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Morphine.
LiothyronineThe serum concentration of Morphine can be decreased when it is combined with Liothyronine.
LiotrixThe serum concentration of Morphine can be decreased when it is combined with Liotrix.
LisdexamfetamineLisdexamfetamine may increase the analgesic activities of Morphine.
LisinoprilThe serum concentration of Morphine can be increased when it is combined with Lisinopril.
LithiumThe risk or severity of adverse effects can be increased when Morphine is combined with Lithium.
LofentanilThe risk or severity of adverse effects can be increased when Morphine is combined with Lofentanil.
LomitapideThe serum concentration of Morphine can be increased when it is combined with Lomitapide.
LoperamideThe serum concentration of Morphine can be increased when it is combined with Loperamide.
LopinavirThe serum concentration of Morphine can be increased when it is combined with Lopinavir.
LoratadineThe serum concentration of Morphine can be increased when it is combined with Loratadine.
LoratadineThe risk or severity of adverse effects can be increased when Morphine is combined with Loratadine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Morphine.
LorcaserinThe metabolism of Morphine can be decreased when combined with Lorcaserin.
LosartanThe serum concentration of Morphine can be increased when it is combined with Losartan.
LovastatinThe metabolism of Morphine can be decreased when combined with Lovastatin.
LoxapineThe risk or severity of adverse effects can be increased when Morphine is combined with Loxapine.
Lu AA21004Morphine may increase the serotonergic activities of Lu AA21004.
Lu AA21004The risk or severity of adverse effects can be increased when Lu AA21004 is combined with Morphine.
LuliconazoleThe serum concentration of Morphine can be increased when it is combined with Luliconazole.
LumacaftorThe serum concentration of Morphine can be decreased when it is combined with Lumacaftor.
LumefantrineThe metabolism of Morphine can be decreased when combined with Lumefantrine.
LurasidoneThe risk or severity of adverse effects can be increased when Morphine is combined with Lurasidone.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Morphine.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Morphine is combined with Magnesium Sulfate.
MannitolThe risk or severity of adverse effects can be increased when Morphine is combined with Mannitol.
MaprotilineThe serum concentration of Morphine can be increased when it is combined with Maprotiline.
MaprotilineThe risk or severity of adverse effects can be increased when Morphine is combined with Maprotiline.
MebanazineThe risk or severity of adverse effects can be increased when Mebanazine is combined with Morphine.
MebendazoleThe serum concentration of Morphine can be increased when it is combined with Mebendazole.
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Morphine.
MeclizineThe risk or severity of adverse effects can be increased when Morphine is combined with Meclizine.
MedetomidineThe risk or severity of adverse effects can be increased when Morphine is combined with Medetomidine.
MefloquineThe serum concentration of Morphine can be increased when it is combined with Mefloquine.
Megestrol acetateThe serum concentration of Morphine can be increased when it is combined with Megestrol acetate.
MelatoninThe risk or severity of adverse effects can be increased when Morphine is combined with Melatonin.
MelperoneThe risk or severity of adverse effects can be increased when Morphine is combined with Melperone.
MephentermineMephentermine may increase the analgesic activities of Morphine.
MepivacaineThe risk or severity of adverse effects can be increased when Morphine is combined with Mepivacaine.
MeprobamateThe serum concentration of Morphine can be increased when it is combined with Meprobamate.
MeprobamateThe risk or severity of adverse effects can be increased when Morphine is combined with Meprobamate.
MersalylThe risk or severity of adverse effects can be increased when Morphine is combined with Mersalyl.
MesoridazineMesoridazine may increase the hypotensive activities of Morphine.
MesoridazineThe risk or severity of adverse effects can be increased when Morphine is combined with Mesoridazine.
MetaxaloneThe risk or severity of adverse effects can be increased when Morphine is combined with Metaxalone.
MethadoneThe serum concentration of Morphine can be increased when it is combined with Methadone.
MethadoneThe risk or severity of adverse effects can be increased when Morphine is combined with Methadone.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Morphine is combined with Methadyl Acetate.
MethamphetamineMethamphetamine may increase the analgesic activities of Morphine.
MethanthelineThe risk or severity of adverse effects can be increased when Methantheline is combined with Morphine.
MethapyrileneThe risk or severity of adverse effects can be increased when Morphine is combined with Methapyrilene.
MethaqualoneThe risk or severity of adverse effects can be increased when Morphine is combined with Methaqualone.
MethazolamideThe risk or severity of adverse effects can be increased when Morphine is combined with Methazolamide.
MethocarbamolThe risk or severity of adverse effects can be increased when Morphine is combined with Methocarbamol.
MethohexitalThe risk or severity of adverse effects can be increased when Morphine is combined with Methohexital.
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Morphine.
MethotrimeprazineMethotrimeprazine may increase the hypotensive activities of Morphine.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Morphine is combined with Methotrimeprazine.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Morphine is combined with Methoxyflurane.
MethsuximideThe risk or severity of adverse effects can be increased when Morphine is combined with Methsuximide.
MethyclothiazideThe risk or severity of adverse effects can be increased when Morphine is combined with Methyclothiazide.
Methylene blueThe risk or severity of adverse effects can be increased when Methylene blue is combined with Morphine.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Morphine is combined with Methylphenobarbital.
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Morphine.
MetixeneThe risk or severity of adverse effects can be increased when Metixene is combined with Morphine.
MetolazoneThe risk or severity of adverse effects can be increased when Morphine is combined with Metolazone.
MetoprololThe serum concentration of Morphine can be increased when it is combined with Metoprolol.
MetyrosineMorphine may increase the sedative activities of Metyrosine.
MibefradilThe serum concentration of Morphine can be increased when it is combined with Mibefradil.
MiconazoleThe serum concentration of Morphine can be increased when it is combined with Miconazole.
MidazolamThe serum concentration of Morphine can be decreased when it is combined with Midazolam.
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Morphine.
MifepristoneThe metabolism of Morphine can be decreased when combined with Mifepristone.
MilnacipranMorphine may increase the serotonergic activities of Milnacipran.
MinaprineThe risk or severity of adverse effects can be increased when Minaprine is combined with Morphine.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Morphine.
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Morphine.
MirabegronThe metabolism of Morphine can be decreased when combined with Mirabegron.
MirtazapineMorphine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Morphine.
MitomycinThe serum concentration of Morphine can be increased when it is combined with Mitomycin.
MitotaneThe serum concentration of Morphine can be decreased when it is combined with Mitotane.
MitoxantroneThe serum concentration of Morphine can be decreased when it is combined with Mitoxantrone.
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Morphine.
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Morphine.
ModafinilThe serum concentration of Morphine can be decreased when it is combined with Modafinil.
MolindoneThe risk or severity of adverse effects can be increased when Morphine is combined with Molindone.
MoricizineMoricizine may increase the hypotensive activities of Morphine.
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Morphine.
N-butylscopolammonium bromideThe risk or severity of adverse effects can be increased when N-butylscopolammonium bromide is combined with Morphine.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Morphine.
NabiloneThe risk or severity of adverse effects can be increased when Morphine is combined with Nabilone.
NadololThe serum concentration of Nadolol can be increased when it is combined with Morphine.
NafcillinThe serum concentration of Morphine can be decreased when it is combined with Nafcillin.
NalbuphineNalbuphine may decrease the analgesic activities of Morphine.
NalbuphineThe risk or severity of adverse effects can be increased when Morphine is combined with Nalbuphine.
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Morphine.
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Morphine.
NaltrexoneThe serum concentration of Morphine can be increased when it is combined with Naltrexone.
NaringeninThe serum concentration of Morphine can be increased when it is combined with Naringenin.
NefazodoneThe serum concentration of Morphine can be decreased when it is combined with Nefazodone.
NelfinavirThe serum concentration of Morphine can be decreased when it is combined with Nelfinavir.
NelfinavirThe serum concentration of Nelfinavir can be increased when it is combined with Morphine.
NeostigmineThe serum concentration of Morphine can be increased when it is combined with Neostigmine.
NetupitantThe serum concentration of Morphine can be increased when it is combined with Netupitant.
NevirapineThe metabolism of Morphine can be decreased when combined with Nevirapine.
NialamideThe risk or severity of adverse effects can be increased when Nialamide is combined with Morphine.
NicardipineThe serum concentration of Morphine can be increased when it is combined with Nicardipine.
NifedipineThe serum concentration of Morphine can be decreased when it is combined with Nifedipine.
NifedipineThe serum concentration of Nifedipine can be increased when it is combined with Morphine.
NilotinibThe metabolism of Morphine can be decreased when combined with Nilotinib.
NilotinibThe serum concentration of Nilotinib can be increased when it is combined with Morphine.
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Morphine.
NisoldipineThe serum concentration of Morphine can be increased when it is combined with Nisoldipine.
NitrazepamThe serum concentration of Morphine can be increased when it is combined with Nitrazepam.
NitrazepamThe risk or severity of adverse effects can be increased when Morphine is combined with Nitrazepam.
NitrendipineThe serum concentration of Morphine can be increased when it is combined with Nitrendipine.
Nitrous oxideThe risk or severity of adverse effects can be increased when Morphine is combined with Nitrous oxide.
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Morphine.
NorethisteroneThe serum concentration of Morphine can be decreased when it is combined with Norethisterone.
NormethadoneThe risk or severity of adverse effects can be increased when Morphine is combined with Normethadone.
NortriptylineThe risk or severity of adverse effects can be increased when Morphine is combined with Nortriptyline.
NVA237The risk or severity of adverse effects can be increased when NVA237 is combined with Morphine.
OctamoxinThe risk or severity of adverse effects can be increased when Octamoxin is combined with Morphine.
OlanzapineMorphine may increase the serotonergic activities of Olanzapine.
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Morphine.
OlaparibThe metabolism of Morphine can be decreased when combined with Olaparib.
OlopatadineThe risk or severity of adverse effects can be increased when Morphine is combined with Olopatadine.
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Morphine.
OmeprazoleThe serum concentration of Morphine can be increased when it is combined with Omeprazole.
OndansetronThe risk or severity of adverse effects can be increased when Morphine is combined with Ondansetron.
OpiumThe risk or severity of adverse effects can be increased when Morphine is combined with Opium.
OrphenadrineMorphine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Morphine.
OsanetantThe risk or severity of adverse effects can be increased when Morphine is combined with Osanetant.
OsimertinibThe serum concentration of Morphine can be increased when it is combined with Osimertinib.
OxazepamThe risk or severity of adverse effects can be increased when Morphine is combined with Oxazepam.
OxprenololThe risk or severity of adverse effects can be increased when Morphine is combined with Oxprenolol.
OxybuprocaineThe risk or severity of adverse effects can be increased when Morphine is combined with Oxybuprocaine.
OxybutyninThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Morphine.
OxycodoneThe risk or severity of adverse effects can be increased when Morphine is combined with Oxycodone.
OxymorphoneThe risk or severity of adverse effects can be increased when Morphine is combined with Oxymorphone.
OxyphenoniumThe risk or severity of adverse effects can be increased when Oxyphenonium is combined with Morphine.
P-NitrophenolThe serum concentration of Morphine can be increased when it is combined with P-Nitrophenol.
PaclitaxelThe serum concentration of Morphine can be increased when it is combined with Paclitaxel.
PalbociclibThe serum concentration of Morphine can be increased when it is combined with Palbociclib.
PaliperidoneThe risk or severity of adverse effects can be increased when Morphine is combined with Paliperidone.
Palmitic AcidThe serum concentration of Morphine can be increased when it is combined with Palmitic Acid.
PancuroniumThe risk or severity of adverse effects can be increased when Pancuronium is combined with Morphine.
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Morphine.
PanobinostatThe metabolism of Morphine can be decreased when combined with Panobinostat.
PantoprazoleThe serum concentration of Morphine can be increased when it is combined with Pantoprazole.
ParaldehydeMorphine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Morphine.
PargylineThe risk or severity of adverse effects can be increased when Pargyline is combined with Morphine.
ParoxetineMorphine may increase the serotonergic activities of Paroxetine.
ParoxetineThe serum concentration of Morphine can be increased when it is combined with Paroxetine.
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Morphine.
Peginterferon alfa-2bThe serum concentration of Morphine can be decreased when it is combined with Peginterferon alfa-2b.
PegvisomantThe therapeutic efficacy of Pegvisomant can be decreased when used in combination with Morphine.
PentazocinePentazocine may decrease the analgesic activities of Morphine.
PentazocineThe risk or severity of adverse effects can be increased when Morphine is combined with Pentazocine.
PentobarbitalThe risk or severity of adverse effects can be increased when Morphine is combined with Pentobarbital.
PentoliniumThe risk or severity of adverse effects can be increased when Pentolinium is combined with Morphine.
PerampanelThe risk or severity of adverse effects can be increased when Morphine is combined with Perampanel.
PerindoprilThe serum concentration of Morphine can be increased when it is combined with Perindopril.
PerospironeThe risk or severity of adverse effects can be increased when Morphine is combined with Perospirone.
PerphenazinePerphenazine may increase the hypotensive activities of Morphine.
PerphenazineThe risk or severity of adverse effects can be increased when Morphine is combined with Perphenazine.
PethidineThe risk or severity of adverse effects can be increased when Morphine is combined with Pethidine.
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Morphine.
PheniprazineThe risk or severity of adverse effects can be increased when Pheniprazine is combined with Morphine.
PhenobarbitalThe serum concentration of Morphine can be decreased when it is combined with Phenobarbital.
PhenobarbitalThe serum concentration of Phenobarbital can be increased when it is combined with Morphine.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Morphine is combined with Phenoxyethanol.
PhenoxypropazineThe risk or severity of adverse effects can be increased when Phenoxypropazine is combined with Morphine.
PhenterminePhentermine may increase the analgesic activities of Morphine.
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Morphine.
PhenytoinThe risk or severity of adverse effects can be increased when Phenytoin is combined with Morphine.
PimozideThe serum concentration of Morphine can be increased when it is combined with Pimozide.
PimozideThe risk or severity of adverse effects can be increased when Morphine is combined with Pimozide.
PioglitazoneThe metabolism of Morphine can be decreased when combined with Pioglitazone.
PipamperoneThe risk or severity of adverse effects can be increased when Morphine is combined with Pipamperone.
PipecuroniumThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Morphine.
PipotiazineThe risk or severity of adverse effects can be increased when Morphine is combined with Pipotiazine.
PirenzepineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Morphine.
PiretanideThe risk or severity of adverse effects can be increased when Morphine is combined with Piretanide.
PirlindoleThe risk or severity of adverse effects can be increased when Pirlindole is combined with Morphine.
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Morphine.
PivhydrazineThe risk or severity of adverse effects can be increased when Pivhydrazine is combined with Morphine.
PizotifenThe risk or severity of adverse effects can be increased when Morphine is combined with Pizotifen.
Platelet Activating FactorThe serum concentration of Morphine can be decreased when it is combined with Platelet Activating Factor.
PolythiazideThe risk or severity of adverse effects can be increased when Morphine is combined with Polythiazide.
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Morphine.
PomalidomideThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Morphine.
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Morphine.
PosaconazoleThe serum concentration of Morphine can be increased when it is combined with Posaconazole.
PotassiumThe risk or severity of adverse effects can be increased when Morphine is combined with Potassium.
Potassium CitrateThe risk or severity of adverse effects can be increased when Morphine is combined with Potassium Citrate.
PramipexoleMorphine may increase the sedative activities of Pramipexole.
PramocaineThe risk or severity of adverse effects can be increased when Morphine is combined with Pramocaine.
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Morphine.
PrazepamThe risk or severity of adverse effects can be increased when Morphine is combined with Prazepam.
PrazosinThe serum concentration of Morphine can be increased when it is combined with Prazosin.
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Morphine.
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Morphine.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Morphine.
PrilocaineThe risk or severity of adverse effects can be increased when Morphine is combined with Prilocaine.
PrimidoneThe risk or severity of adverse effects can be increased when Morphine is combined with Primidone.
ProbenecidThe serum concentration of Morphine can be increased when it is combined with Probenecid.
ProcaineThe risk or severity of adverse effects can be increased when Morphine is combined with Procaine.
ProchlorperazineProchlorperazine may increase the hypotensive activities of Morphine.
ProchlorperazineThe risk or severity of adverse effects can be increased when Morphine is combined with Prochlorperazine.
ProcyclidineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Morphine.
ProgesteroneThe serum concentration of Morphine can be decreased when it is combined with Progesterone.
ProgesteroneThe serum concentration of Progesterone can be increased when it is combined with Morphine.
PromazinePromazine may increase the hypotensive activities of Morphine.
PromazineThe risk or severity of adverse effects can be increased when Morphine is combined with Promazine.
PromethazinePromethazine may increase the hypotensive activities of Morphine.
PromethazineThe risk or severity of adverse effects can be increased when Morphine is combined with Promethazine.
PropafenoneThe serum concentration of Morphine can be increased when it is combined with Propafenone.
PropanthelineThe risk or severity of adverse effects can be increased when Propantheline is combined with Morphine.
ProparacaineThe risk or severity of adverse effects can be increased when Morphine is combined with Proparacaine.
PropofolThe risk or severity of adverse effects can be increased when Morphine is combined with Propofol.
PropoxycaineThe risk or severity of adverse effects can be increased when Morphine is combined with Propoxycaine.
PropranololThe serum concentration of Propranolol can be increased when it is combined with Morphine.
ProtriptylineThe serum concentration of Morphine can be increased when it is combined with Protriptyline.
ProtriptylineThe risk or severity of adverse effects can be increased when Morphine is combined with Protriptyline.
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Morphine.
PSD502The risk or severity of adverse effects can be increased when Morphine is combined with PSD502.
QuazepamThe risk or severity of adverse effects can be increased when Morphine is combined with Quazepam.
QuercetinThe serum concentration of Morphine can be increased when it is combined with Quercetin.
QuetiapineThe serum concentration of Quetiapine can be increased when it is combined with Morphine.
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Morphine.
QuinacrineThe serum concentration of Morphine can be increased when it is combined with Quinacrine.
QuinethazoneThe risk or severity of adverse effects can be increased when Morphine is combined with Quinethazone.
QuinidineThe risk or severity of adverse effects can be increased when Quinidine is combined with Morphine.
QuinidineThe serum concentration of Quinidine can be increased when it is combined with Morphine.
QuinineThe serum concentration of Morphine can be increased when it is combined with Quinine.
RabeprazoleThe metabolism of Morphine can be decreased when combined with Rabeprazole.
RamelteonThe risk or severity of adverse effects can be increased when Morphine is combined with Ramelteon.
RamosetronMorphine may increase the constipating activities of Ramosetron.
RanitidineThe serum concentration of Morphine can be increased when it is combined with Ranitidine.
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Morphine.
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Morphine.
ReboxetineThe serum concentration of Morphine can be increased when it is combined with Reboxetine.
RegorafenibThe serum concentration of Morphine can be increased when it is combined with Regorafenib.
RemifentanilThe risk or severity of adverse effects can be increased when Morphine is combined with Remifentanil.
RemoxiprideThe risk or severity of adverse effects can be increased when Morphine is combined with Remoxipride.
ReserpineThe serum concentration of Morphine can be decreased when it is combined with Reserpine.
ReserpineThe serum concentration of Reserpine can be increased when it is combined with Morphine.
RifabutinThe metabolism of Morphine can be increased when combined with Rifabutin.
RifampicinThe serum concentration of Morphine can be decreased when it is combined with Rifampicin.
RifampicinThe serum concentration of Rifampicin can be increased when it is combined with Morphine.
RifapentineThe metabolism of Morphine can be increased when combined with Rifapentine.
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Morphine.
RilpivirineThe serum concentration of Morphine can be increased when it is combined with Rilpivirine.
RisperidoneThe serum concentration of Risperidone can be increased when it is combined with Morphine.
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Morphine.
RitonavirThe serum concentration of Morphine can be decreased when it is combined with Ritonavir.
RitonavirThe serum concentration of Ritonavir can be increased when it is combined with Morphine.
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Morphine.
RolapitantThe serum concentration of Morphine can be increased when it is combined with Rolapitant.
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Morphine.
RomifidineThe risk or severity of adverse effects can be increased when Morphine is combined with Romifidine.
RopiniroleMorphine may increase the sedative activities of Ropinirole.
RopiniroleThe metabolism of Morphine can be decreased when combined with Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Morphine is combined with Ropivacaine.
RosiglitazoneThe metabolism of Morphine can be decreased when combined with Rosiglitazone.
RotigotineMorphine may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Morphine.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Morphine is combined with S-Ethylisothiourea.
SafrazineThe risk or severity of adverse effects can be increased when Safrazine is combined with Morphine.
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Morphine.
SaquinavirThe serum concentration of Morphine can be decreased when it is combined with Saquinavir.
SaquinavirThe serum concentration of Saquinavir can be increased when it is combined with Morphine.
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Morphine.
Scopolamine butylbromideThe risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Morphine.
SecobarbitalThe risk or severity of adverse effects can be increased when Morphine is combined with Secobarbital.
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Morphine.
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Morphine.
SertindoleThe risk or severity of adverse effects can be increased when Morphine is combined with Sertindole.
SertralineMorphine may increase the serotonergic activities of Sertraline.
SertralineThe serum concentration of Morphine can be increased when it is combined with Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Morphine is combined with Sevoflurane.
SildenafilThe metabolism of Morphine can be decreased when combined with Sildenafil.
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Morphine.
SiltuximabThe serum concentration of Morphine can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Morphine can be increased when it is combined with Simeprevir.
SimvastatinThe serum concentration of Morphine can be increased when it is combined with Simvastatin.
SirolimusThe serum concentration of Morphine can be decreased when it is combined with Sirolimus.
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Morphine.
Sodium oxybateThe risk or severity of adverse effects can be increased when Morphine is combined with Sodium oxybate.
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Morphine.
SolifenacinThe risk or severity of adverse effects can be increased when Solifenacin is combined with Morphine.
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Morphine.
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Morphine.
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Morphine.
SpironolactoneThe risk or severity of adverse effects can be increased when Morphine is combined with Spironolactone.
SpironolactoneThe serum concentration of Morphine can be increased when it is combined with Spironolactone.
St. John's WortThe serum concentration of Morphine can be decreased when it is combined with St. John's Wort.
StaurosporineThe serum concentration of Morphine can be increased when it is combined with Staurosporine.
StiripentolThe risk or severity of adverse effects can be increased when Morphine is combined with Stiripentol.
StreptozocinThe serum concentration of Morphine can be decreased when it is combined with Streptozocin.
SuccinylcholineSuccinylcholine may increase the bradycardic activities of Morphine.
SufentanilThe risk or severity of adverse effects can be increased when Morphine is combined with Sufentanil.
SulfamethoxazoleThe metabolism of Morphine can be decreased when combined with Sulfamethoxazole.
SulfinpyrazoneThe serum concentration of Morphine can be increased when it is combined with Sulfinpyrazone.
SulfisoxazoleThe metabolism of Morphine can be decreased when combined with Sulfisoxazole.
SulpirideThe risk or severity of adverse effects can be increased when Morphine is combined with Sulpiride.
SumatriptanThe serum concentration of Morphine can be increased when it is combined with Sumatriptan.
SunitinibThe serum concentration of Morphine can be increased when it is combined with Sunitinib.
SuvorexantThe risk or severity of adverse effects can be increased when Morphine is combined with Suvorexant.
TacrineThe serum concentration of Morphine can be increased when it is combined with Tacrine.
TacrolimusThe serum concentration of Morphine can be decreased when it is combined with Tacrolimus.
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Morphine.
TamoxifenThe serum concentration of Morphine can be decreased when it is combined with Tamoxifen.
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Morphine.
TapentadolThe risk or severity of adverse effects can be increased when Morphine is combined with Tapentadol.
TasimelteonThe risk or severity of adverse effects can be increased when Morphine is combined with Tasimelteon.
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Morphine.
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Morphine.
TelaprevirThe metabolism of Morphine can be decreased when combined with Telaprevir.
TelaprevirThe serum concentration of Telaprevir can be increased when it is combined with Morphine.
TelithromycinThe metabolism of Morphine can be decreased when combined with Telithromycin.
TelmisartanThe serum concentration of Morphine can be increased when it is combined with Telmisartan.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Morphine.
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Morphine.
TerazosinThe serum concentration of Morphine can be increased when it is combined with Terazosin.
TerbinafineThe metabolism of Morphine can be decreased when combined with Terbinafine.
TerfenadineThe serum concentration of Morphine can be increased when it is combined with Terfenadine.
TeriflunomideThe metabolism of Morphine can be decreased when combined with Teriflunomide.
TesmilifeneThe serum concentration of Morphine can be decreased when it is combined with Tesmilifene.
TestosteroneThe serum concentration of Morphine can be increased when it is combined with Testosterone.
TetrabenazineThe risk or severity of adverse effects can be increased when Morphine is combined with Tetrabenazine.
TetracaineThe risk or severity of adverse effects can be increased when Morphine is combined with Tetracaine.
TetrodotoxinThe risk or severity of adverse effects can be increased when Morphine is combined with Tetrodotoxin.
ThalidomideMorphine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Morphine.
TheobromineThe risk or severity of adverse effects can be increased when Morphine is combined with Theobromine.
ThiamylalThe risk or severity of adverse effects can be increased when Morphine is combined with Thiamylal.
ThiethylperazineThiethylperazine may increase the hypotensive activities of Morphine.
ThiopentalThe risk or severity of adverse effects can be increased when Morphine is combined with Thiopental.
ThioridazineThioridazine may increase the hypotensive activities of Morphine.
ThioridazineThe risk or severity of adverse effects can be increased when Morphine is combined with Thioridazine.
ThiothixeneThe risk or severity of adverse effects can be increased when Morphine is combined with Thiothixene.
TiagabineThe risk or severity of adverse effects can be increased when Morphine is combined with Tiagabine.
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Morphine.
TiclopidineThe metabolism of Morphine can be decreased when combined with Ticlopidine.
TicrynafenThe risk or severity of adverse effects can be increased when Morphine is combined with Ticrynafen.
TiletamineThe risk or severity of adverse effects can be increased when Morphine is combined with Tiletamine.
TimololThe serum concentration of Timolol can be increased when it is combined with Morphine.
TiotropiumThe risk or severity of adverse effects can be increased when Tiotropium is combined with Morphine.
TipranavirThe metabolism of Morphine can be decreased when combined with Tipranavir.
TizanidineThe risk or severity of adverse effects can be increased when Morphine is combined with Tizanidine.
TocilizumabThe serum concentration of Morphine can be decreased when it is combined with Tocilizumab.
TolcaponeThe risk or severity of adverse effects can be increased when Morphine is combined with Tolcapone.
ToloxatoneThe risk or severity of adverse effects can be increased when Toloxatone is combined with Morphine.
TolterodineThe risk or severity of adverse effects can be increased when Tolterodine is combined with Morphine.
TolvaptanThe risk or severity of adverse effects can be increased when Morphine is combined with Tolvaptan.
TolvaptanThe serum concentration of Morphine can be increased when it is combined with Tolvaptan.
TopiramateThe risk or severity of adverse effects can be increased when Morphine is combined with Topiramate.
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Morphine.
TorasemideThe risk or severity of adverse effects can be increased when Morphine is combined with Torasemide.
ToremifeneThe serum concentration of Toremifene can be increased when it is combined with Morphine.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Morphine.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Morphine.
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Morphine.
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Morphine.
TrazodoneMorphine may increase the serotonergic activities of Trazodone.
TrazodoneThe serum concentration of Morphine can be decreased when it is combined with Trazodone.
TriamtereneThe risk or severity of adverse effects can be increased when Morphine is combined with Triamterene.
TriazolamThe risk or severity of adverse effects can be increased when Morphine is combined with Triazolam.
TrichlormethiazideThe risk or severity of adverse effects can be increased when Morphine is combined with Trichlormethiazide.
TrifluoperazineTrifluoperazine may increase the hypotensive activities of Morphine.
TrifluoperazineThe risk or severity of adverse effects can be increased when Morphine is combined with Trifluoperazine.
TriflupromazineTriflupromazine may increase the hypotensive activities of Morphine.
TriflupromazineThe risk or severity of adverse effects can be increased when Morphine is combined with Triflupromazine.
TrihexyphenidylThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Morphine.
TrimethaphanThe risk or severity of adverse effects can be increased when Trimethaphan is combined with Morphine.
TrimethoprimThe serum concentration of Morphine can be decreased when it is combined with Trimethoprim.
TrimipramineThe serum concentration of Morphine can be increased when it is combined with Trimipramine.
TrimipramineThe risk or severity of adverse effects can be increased when Morphine is combined with Trimipramine.
TriprolidineThe risk or severity of adverse effects can be increased when Morphine is combined with Triprolidine.
TroleandomycinThe serum concentration of Morphine can be increased when it is combined with Troleandomycin.
TropicamideThe risk or severity of adverse effects can be increased when Tropicamide is combined with Morphine.
TrospiumThe risk or severity of adverse effects can be increased when Trospium is combined with Morphine.
TubocurarineThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Morphine.
UlaritideThe risk or severity of adverse effects can be increased when Morphine is combined with Ularitide.
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Morphine.
UmeclidiniumThe risk or severity of adverse effects can be increased when Umeclidinium is combined with Morphine.
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Morphine.
Valproic AcidThe risk or severity of adverse effects can be increased when Morphine is combined with Valproic Acid.
VecuroniumThe risk or severity of adverse effects can be increased when Vecuronium is combined with Morphine.
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Morphine.
VenlafaxineThe metabolism of Morphine can be decreased when combined with Venlafaxine.
VenlafaxineThe serum concentration of Venlafaxine can be increased when it is combined with Morphine.
VerapamilThe metabolism of Morphine can be decreased when combined with Verapamil.
VerapamilThe serum concentration of Verapamil can be increased when it is combined with Morphine.
VigabatrinThe risk or severity of adverse effects can be increased when Morphine is combined with Vigabatrin.
VilazodoneMorphine may increase the serotonergic activities of Vilazodone.
VinblastineThe serum concentration of Morphine can be decreased when it is combined with Vinblastine.
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Morphine.
VincristineThe serum concentration of Vincristine can be increased when it is combined with Morphine.
VincristineThe serum concentration of Morphine can be decreased when it is combined with Vincristine.
VinorelbineThe serum concentration of Morphine can be increased when it is combined with Vinorelbine.
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Morphine.
VoriconazoleThe metabolism of Morphine can be decreased when combined with Voriconazole.
VortioxetineMorphine may increase the serotonergic activities of Vortioxetine.
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Morphine.
XylazineThe risk or severity of adverse effects can be increased when Morphine is combined with Xylazine.
ZaleplonThe risk or severity of adverse effects can be increased when Morphine is combined with Zaleplon.
ZiconotideThe risk or severity of adverse effects can be increased when Morphine is combined with Ziconotide.
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Morphine.
ZimelidineMorphine may increase the serotonergic activities of Zimelidine.
ZimelidineThe serum concentration of Morphine can be increased when it is combined with Zimelidine.
ZiprasidoneThe metabolism of Morphine can be decreased when combined with Ziprasidone.
ZiprasidoneThe risk or severity of adverse effects can be increased when Morphine is combined with Ziprasidone.
ZolazepamThe risk or severity of adverse effects can be increased when Morphine is combined with Zolazepam.
ZolpidemThe risk or severity of adverse effects can be increased when Morphine is combined with Zolpidem.
ZonisamideThe risk or severity of adverse effects can be increased when Morphine is combined with Zonisamide.
ZopicloneThe risk or severity of adverse effects can be increased when Morphine is combined with Zopiclone.
ZotepineThe risk or severity of adverse effects can be increased when Morphine is combined with Zotepine.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Morphine is combined with Zuclopenthixol.
Food Interactions
  • Avoid alcohol.
  • Take with food.
  • To avoid constipation: increase your daily intake of fiber (beans, whole grains, vegetables).

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Voltage-gated calcium channel activity
Specific Function:
Receptor for endogenous opioids such as beta-endorphin and endomorphin. Receptor for natural and synthetic opioids including morphine, heroin, DAMGO, fentanyl, etorphine, buprenorphin and methadone. Agonist binding to the receptor induces coupling to an inactive GDP-bound heterotrimeric G-protein complex and subsequent exchange of GDP for GTP in the G-protein alpha subunit leading to dissociati...
Gene Name:
OPRM1
Uniprot ID:
P35372
Molecular Weight:
44778.855 Da
References
  1. Yamada H, Shimoyama N, Sora I, Uhl GR, Fukuda Y, Moriya H, Shimoyama M: Morphine can produce analgesia via spinal kappa opioid receptors in the absence of mu opioid receptors. Brain Res. 2006 Apr 14;1083(1):61-9. Epub 2006 Mar 10. [PubMed:16530171 ]
  2. Choi HS, Kim CS, Hwang CK, Song KY, Wang W, Qiu Y, Law PY, Wei LN, Loh HH: The opioid ligand binding of human mu-opioid receptor is modulated by novel splice variants of the receptor. Biochem Biophys Res Commun. 2006 May 19;343(4):1132-40. Epub 2006 Mar 23. [PubMed:16580639 ]
  3. Castro RR, Cunha FQ, Silva FS Jr, Rocha FA: A quantitative approach to measure joint pain in experimental osteoarthritis--evidence of a role for nitric oxide. Osteoarthritis Cartilage. 2006 Aug;14(8):769-76. Epub 2006 Mar 31. [PubMed:16580848 ]
  4. Johnson EA, Oldfield S, Braksator E, Gonzalez-Cuello A, Couch D, Hall KJ, Mundell SJ, Bailey CP, Kelly E, Henderson G: Agonist-selective mechanisms of mu-opioid receptor desensitization in human embryonic kidney 293 cells. Mol Pharmacol. 2006 Aug;70(2):676-85. Epub 2006 May 8. [PubMed:16682505 ]
  5. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  6. doi:10.1021/cn9000236 [Link]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Opioid receptor activity
Specific Function:
G-protein coupled opioid receptor that functions as receptor for endogenous alpha-neoendorphins and dynorphins, but has low affinity for beta-endorphins. Also functions as receptor for various synthetic opioids and for the psychoactive diterpene salvinorin A. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates th...
Gene Name:
OPRK1
Uniprot ID:
P41145
Molecular Weight:
42644.665 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Leventhal L, Silva RM, Rossi GC, Pasternak GW, Bodnar RJ: Morphine-6beta-glucuronide-induced hyperphagia: characterization of opioid action by selective antagonists and antisense mapping in rats. J Pharmacol Exp Ther. 1998 Nov;287(2):538-44. [PubMed:9808678 ]
  4. Kozak CA, Filie J, Adamson MC, Chen Y, Yu L: Murine chromosomal location of the mu and kappa opioid receptor genes. Genomics. 1994 Jun;21(3):659-61. [PubMed:7959748 ]
  5. Teodorov E, Modena CC, Sukikara MH, Felicio LF: Preliminary study of the effects of morphine treatment on opioid receptor gene expression in brain structures of the female rat. Neuroscience. 2006 Sep 1;141(3):1225-31. Epub 2006 Jun 6. [PubMed:16753266 ]
  6. doi:10.1021/cn9000236 [Link]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Opioid receptor activity
Specific Function:
G-protein coupled receptor that functions as receptor for endogenous enkephalins and for a subset of other opioids. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling leads to the inhibition of adenylate cyclase activity. Inhibits neurot...
Gene Name:
OPRD1
Uniprot ID:
P41143
Molecular Weight:
40368.235 Da
References
  1. Yamada H, Shimoyama N, Sora I, Uhl GR, Fukuda Y, Moriya H, Shimoyama M: Morphine can produce analgesia via spinal kappa opioid receptors in the absence of mu opioid receptors. Brain Res. 2006 Apr 14;1083(1):61-9. Epub 2006 Mar 10. [PubMed:16530171 ]
  2. Dortch-Carnes J, Russell KR: Morphine-induced reduction of intraocular pressure and pupil diameter: role of nitric oxide. Pharmacology. 2006;77(1):17-24. Epub 2006 Mar 13. [PubMed:16534251 ]
  3. Koch T, Wu DF, Yang LQ, Brandenburg LO, Hollt V: Role of phospholipase D2 in the agonist-induced and constitutive endocytosis of G-protein coupled receptors. J Neurochem. 2006 Apr;97(2):365-72. Epub 2006 Mar 15. [PubMed:16539674 ]
  4. Galeotti N, Stefano GB, Guarna M, Bianchi E, Ghelardini C: Signaling pathway of morphine induced acute thermal hyperalgesia in mice. Pain. 2006 Aug;123(3):294-305. Epub 2006 May 2. [PubMed:16650582 ]
  5. Asensio VJ, Miralles A, Garcia-Sevilla JA: Stimulation of mitogen-activated protein kinase kinases (MEK1/2) by mu-, delta- and kappa-opioid receptor agonists in the rat brain: regulation by chronic morphine and opioid withdrawal. Eur J Pharmacol. 2006 Jun 6;539(1-2):49-56. Epub 2006 Apr 6. [PubMed:16678156 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  7. Kieffer BL, Gaveriaux-Ruff C: Exploring the opioid system by gene knockout. Prog Neurobiol. 2002 Apr;66(5):285-306. [PubMed:12015197 ]
  8. doi:10.1021/cn9000236 [Link]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Molecular Weight:
55824.275 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Glucuronosyltransferase activity
Specific Function:
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds.Its unique specificity for 3,4-catechol estrogens and estriol suggests it may play an important role in regulating the level and activity of these potent and active estrogen metabolites. Is also active with androsterone, hyodeoxycholic acid and tetrachlorocatechol...
Gene Name:
UGT2B7
Uniprot ID:
P16662
Molecular Weight:
60694.12 Da
References
  1. Coffman BL, Rios GR, King CD, Tephly TR: Human UGT2B7 catalyzes morphine glucuronidation. Drug Metab Dispos. 1997 Jan;25(1):1-4. [PubMed:9010622 ]
  2. Takeda S, Ishii Y, Iwanaga M, Mackenzie PI, Nagata K, Yamazoe Y, Oguri K, Yamada H: Modulation of UDP-glucuronosyltransferase function by cytochrome P450: evidence for the alteration of UGT2B7-catalyzed glucuronidation of morphine by CYP3A4. Mol Pharmacol. 2005 Mar;67(3):665-72. Epub 2004 Dec 20. [PubMed:15611481 ]
  3. Yamada H, Ishii K, Ishii Y, Ieiri I, Nishio S, Morioka T, Oguri K: Formation of highly analgesic morphine-6-glucuronide following physiologic concentration of morphine in human brain. J Toxicol Sci. 2003 Dec;28(5):395-401. [PubMed:14746343 ]
  4. Abildskov K, Weldy P, Garland M: Molecular cloning of the baboon UDP-glucuronosyltransferase 2B gene family and their activity in conjugating morphine. Drug Metab Dispos. 2010 Apr;38(4):545-53. doi: 10.1124/dmd.109.030635. Epub 2010 Jan 13. [PubMed:20071451 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid binding
Specific Function:
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform glucuronidates bilirubin IX-alpha to form both the IX-alpha-C8 and IX-alpha-C12 monoconjugates and diconjugate. Is also able to catalyze the glucuronidation of 17beta-estradiol, 17alpha-ethinylestradiol, 1-hydroxypyrene, 4-methylumbelliferone, 1-naph...
Gene Name:
UGT1A1
Uniprot ID:
P22309
Molecular Weight:
59590.91 Da
References
  1. Ohno S, Kawana K, Nakajin S: Contribution of UDP-glucuronosyltransferase 1A1 and 1A8 to morphine-6-glucuronidation and its kinetic properties. Drug Metab Dispos. 2008 Apr;36(4):688-94. doi: 10.1124/dmd.107.019281. Epub 2008 Jan 10. [PubMed:18187562 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid binding
Specific Function:
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. Isoform 2 lacks transferase activity but acts as a negative regulator of isoform 1.
Gene Name:
UGT1A8
Uniprot ID:
Q9HAW9
Molecular Weight:
59741.035 Da
References
  1. Ohno S, Kawana K, Nakajin S: Contribution of UDP-glucuronosyltransferase 1A1 and 1A8 to morphine-6-glucuronidation and its kinetic properties. Drug Metab Dispos. 2008 Apr;36(4):688-94. doi: 10.1124/dmd.107.019281. Epub 2008 Jan 10. [PubMed:18187562 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Glucuronosyltransferase activity
Specific Function:
UDPGTs are of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isozyme displays activity toward several classes of xenobiotic substrates, including simple phenolic compounds, 7-hydroxylated coumarins, flavonoids, anthraquinones, and certain drugs and their hydroxylated metabolites. It also catalyzes the glucuronidatio...
Gene Name:
UGT2B15
Uniprot ID:
P54855
Molecular Weight:
61035.815 Da
References
  1. Abildskov K, Weldy P, Garland M: Molecular cloning of the baboon UDP-glucuronosyltransferase 2B gene family and their activity in conjugating morphine. Drug Metab Dispos. 2010 Apr;38(4):545-53. doi: 10.1124/dmd.109.030635. Epub 2010 Jan 13. [PubMed:20071451 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Glucuronosyltransferase activity
Specific Function:
UDPGTs are of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isozyme is active on polyhydroxylated estrogens (such as estriol, 4-hydroxyestrone and 2-hydroxyestriol) and xenobiotics (such as 4-methylumbelliferone, 1-naphthol, 4-nitrophenol, 2-aminophenol, 4-hydroxybiphenyl and menthol). It is capable of 6 alpha-hydr...
Gene Name:
UGT2B4
Uniprot ID:
P06133
Molecular Weight:
60512.035 Da
References
  1. Abildskov K, Weldy P, Garland M: Molecular cloning of the baboon UDP-glucuronosyltransferase 2B gene family and their activity in conjugating morphine. Drug Metab Dispos. 2010 Apr;38(4):545-53. doi: 10.1124/dmd.109.030635. Epub 2010 Jan 13. [PubMed:20071451 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Retinoic acid binding
Specific Function:
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. Isoform 2 lacks transferase activity but acts as a negative regulator of isoform 1.
Gene Name:
UGT1A3
Uniprot ID:
P35503
Molecular Weight:
60337.835 Da
References
  1. Green MD, King CD, Mojarrabi B, Mackenzie PI, Tephly TR: Glucuronidation of amines and other xenobiotics catalyzed by expressed human UDP-glucuronosyltransferase 1A3. Drug Metab Dispos. 1998 Jun;26(6):507-12. [PubMed:9616184 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Schwab D, Fischer H, Tabatabaei A, Poli S, Huwyler J: Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery. J Med Chem. 2003 Apr 24;46(9):1716-25. [PubMed:12699389 ]
  2. Troutman MD, Thakker DR: Novel experimental parameters to quantify the modulation of absorptive and secretory transport of compounds by P-glycoprotein in cell culture models of intestinal epithelium. Pharm Res. 2003 Aug;20(8):1210-24. [PubMed:12948019 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 25, 2016 02:51